

The Western Journal of Medicine

SINCE 1902

ISSN 0093-0415

731 MARKET STREET • SAN FRANCISCO, CALIFORNIA 94103 • TELEPHONE (415) 777-2000

MALCOLM S. M. WATTS, MD, *Editor*
LLOYD H. SMITH, JR, MD, *Associate Editor*
DAVID GREER, *Managing Editor*
SALLY LINEBARGER, *Assistant to Managing Editor*

VAL BOSMOE, *Editorial Assistant*
JANICE ANDERSEN, *Copy Editor*
MARY KAY COWANS, *Advertising Production Manager*
KEVIN MCKINNEY, *Circulation Coordinator*

editorial communications to DR WATTS • business communications to MR GREER

Official Journal of the California Medical Association, the Idaho Medical Association, the Nevada State Medical Association, the New Mexico Medical Society, the Utah State Medical Association, the Washington State Medical Association and the Wyoming Medical Society.

Affiliated Scientific Societies: the Western Association of Physicians; the Western Society for Clinical Investigation; the Western Section, American Federation for Clinical Research; the Western Society for Pediatric Research; the Western Region, Society for Investigative Dermatology.

EDITORIAL BOARD

Chairman of the Board

Malcolm S. M. Watts, San Francisco, Calif

Associate Editor

Lloyd H. Smith, Jr, San Francisco, Calif

Editor for Clinical Investigation

R. Paul Robertson, Seattle, Wash

Special Editor for Idaho

E. R. W. Fox, Coeur d'Alene, Idaho

Special Editor for Nevada

Owen C. Peck, Reno, Nev

Special Editor for New Mexico

Marcus J. Smith, Santa Fe, NM

Special Editor for Utah

John H. Holbrook, Salt Lake City, Utah

Special Editor for Washington

David Hopkins, Federal Way, Wash

Allergy

Harold S. Novey, Orange, Calif
Abba I. Terr, San Francisco, Calif

Anesthesiology

Ronald L. Katz, Los Angeles, Calif

Cardiac and Thoracic Surgery

John E. Connolly, Irvine, Calif
Albert Starr, Portland, Ore

Chest Diseases

Roger K. Larson, Fresno, Calif
Thomas L. Petty, Denver, Colo

Dermatology

John H. Epstein, San Francisco, Calif
George F. Odland, Seattle, Wash
Richard B. Stoughton, San Diego, Calif

Emergency Medicine

W. Richard Bukata, Van Nuys, Calif
Clark Chipman, Portland, Ore
Thomas Elmendorf, Davis, Calif

General and Family Practice

Harmon E. Holverson, Emmett, Idaho
Daniel D. Roberts, Central Point, Ore

General Surgery

John Wesley Batdorf, Las Vegas, Nev
Daniel T. Cloud, Phoenix, Ariz
Paul A. Ebert, San Francisco, Calif
Lucius D. Hill, Seattle, Wash
Frank G. Moody, Houston, Tex

Industrial Medicine and Toxicology

Thomas H. Milby, Berkeley, Calif

Internal Medicine

Robert W. Burroughs, Spokane, Wash
Theodore C. Eickhoff, Denver, Colo
Robert L. Hare, Portland, Ore
Robert H. Moser, Philadelphia, Pa
George A. Porter, Portland, Ore
Helen M. Ranney, San Diego, Calif
David D. Ulmer, Los Angeles, Calif
Edgar Wayburn, San Francisco, Calif
Ralph C. Williams, Jr, Albuquerque, NM

Neurology

Pierre M. Dreyfus, Sacramento, Calif
Philip D. Swanson, Seattle, Wash
W. C. Wiederholt, La Jolla, Calif

Neurosurgery

John R. Green, Phoenix, Ariz
Arthur A. Ward, Jr, Seattle, Wash
Charles B. Wilson, San Francisco, Calif

Nuclear Medicine

Joseph P. Kriss, Stanford, Calif

Obstetrics and Gynecology

Ralph C. Benson, Portland, Ore
Ralph W. Hale, Honolulu, Hawaii
W. LeRoy Heinrichs, Stanford, Calif
Morton A. Stenchever, Seattle, Wash

Ophthalmology

Robert S. Hepler, Los Angeles, Calif
Bruce E. Spivey, San Francisco, Calif

Orthopedics

Ernest M. Burgess, Seattle, Wash
Duane M. Kline, Jr, Cheyenne, Wyo

Otolaryngology

Roger Boles, San Francisco, Calif
Mansfield F. W. Smith, San Jose, Calif

Pathology

Richard L. Kempson, Stanford, Calif

Pediatrics

Louis K. Diamond, San Francisco, Calif
William L. Nyhan, San Diego, Calif
Irving Schulman, Stanford, Calif
Arnold L. Smith, Seattle, Wash

Pharmacology

George N. Aagaard, Seattle, Wash

Physical Medicine and Rehabilitation

Glenn G. Reynolds, San Jose, Calif

Plastic Surgery

Richard P. Jobe, Los Altos, Calif
N. John Wilde, Fresno, Calif

Psychiatry

Carl Eisdorfer, Bronx, NY
Alan I. Levenson, Tucson, Ariz
Helen Tausend, Beverly Hills, Calif
Joe Paul Tupin, Sacramento, Calif

Public Health

J. M. Stubblebine, Greenbrae, Calif

Radiology

M. Paul Capp, Tucson, Ariz
Melvin M. Figley, Seattle, Wash
Marshall Rowen, Orange, Calif

Urology

Richard Middleton, Salt Lake City, Utah
Thomas A. Stamey, Stanford, Calif

Consulting Editor

Medical Services and Health Care
Paul J. Sanazaro, Berkeley, Calif

ADVERTISING INFORMATION

Advertising Sales Representatives

EAST and MIDWEST: Saul G. Hornik, SGH, Inc., 12 Court Street, Freehold, NJ 07728 • (201) 462-8004

WEST: Media Services—Darien DeLorenzo, Lynne Jeffes, 207 Day Street, San Francisco, CA 94131 • (415) 550-0519/348-7478

CLASSIFIED: 731 Market Street, San Francisco, CA 94103 • Tel: (415) 777-2000, Ex. 220/777-0424

Advertisements—THE WESTERN JOURNAL OF MEDICINE is published the first week of each month. Advertising copy must be received not later than the first of the month preceding issue. Advertising rates will be sent on request. Acceptance of advertising is contingent upon approval by the Advertising Committee. *The journal reserves the right to reject any advertisement.*

SUBSCRIPTION INFORMATION

The subscription price per year is \$10 in the United States and Canada; \$18 in all other countries. Single copies are \$2. Address all subscription communications to THE WESTERN JOURNAL OF MEDICINE Circulation, 731 Market St., San Francisco, CA 94103 • Tel: (415) 777-2000, Ex 154.

Allow six weeks for subscriptions to begin. Past issues must be bought indi-

vidually. So long as reserve stocks are available, missing issue requests from subscribers are honored for up to six months after the issue date. Thereafter, the single copy rate of \$2.00 is applicable for each issue available.

Change of Address—Requests for change of address should give both the old and new address. Allow six weeks for changeover.

SUBMITTING MANUSCRIPTS

"Information for Authors"—A complete guide to manuscript submission and journal style is available on request and also appears in each January and July issue.

Responsibilities for Statements and Conclusions—Authors are responsible for all statements, conclusions and methods of presenting their subjects. These may or may not be in harmony with the views of the editorial staff. It is aimed to permit authors to have as wide latitude as the general policy of the journal and the demands on its space may permit. The right to reduce, revise or reject any manuscript is always reserved. Articles are accepted for publication on condition that they are contributed solely to this journal.

Manuscripts—Ordinarily manuscripts should not exceed 3,000 words (less than 15 typed double-spaced pages). The original manuscript and two copies should be submitted, typed double-spaced throughout. If photographic illustrations are desired, three sets of clear, unmounted black and white glossy prints should be supplied.

For line drawings, original artwork or glossy prints are acceptable. Tables should be typed on separate sheets of paper.

Clinical Investigation Section—Articles that authors wish to have considered for the Clinical Investigation section should be so designated in the transmittal letter. The type of articles appropriate for this section are those that describe experimental work in humans that extensively and prospectively examines scientific hypotheses relating to disease. An article describing a single case report will not normally be considered appropriate for this section.

References—References should conform to the following order: name of author, title of article, name of periodical, year of publication, month and volume with inclusive pages—i.e., Lee GS: The heart rhythm following therapy with digitalis—Theory and practice. Arch Int Med 1979 Mar; 44:554-562. They should be listed in the order in which they are cited in the text, numbered in sequence and punctuated as above.

Reprints—Reprints are available to authors at established standard rates.

PUBLISHER

Copyright 1983 by the California Medical Association • Owned and Published by the California Medical Association.

All material subject to this copyright appearing in THE WESTERN JOURNAL OF MEDICINE may be photocopied for the noncommercial purpose of scientific or educational advancement. Volumes begin with January and July.

POLICY COMMITTEE

Charles M. Hair, MD
Robert D. Burnett, MD
Gladden V. Elliott, MD

Richard F. Corlin, MD

Clarence S. Avery, MD

Philipp M. Lippe, MD

Malcolm S. M. Watts, MD

"Entered as second class matter at the post office in San Francisco under the Act of March 3, 1879." Acceptable for mailing at special rate of postage provided for in Section 1103, Act of October 3, 1917, authorized August 10, 1918. Publication Number 084480.

Continuing Medical Education

California, Hawaii, Nevada

Alaska • Idaho • Montana • New Mexico • Oregon • Utah • Washington • Wyoming

CALIFORNIA, HAWAII and NEVADA

This listing of continuing education programs in California, Hawaii and Nevada is supplied by the Committee on Continuing Medical Education of the California Medical Association. All courses and meetings listed have been approved for Category I credit toward the CMA Certificate in Continuing Medical Education. To have accredited courses listed here, please send information at least two months in advance to Department of Continuing Medical Education, California Medical Association, 731 Market Street, San Francisco 94103; or phone (415) 777-2000, ext. 139. For a list of organizations approved for Category I credit toward the CMA Certificate in Continuing Medical Education or for more information on accreditation or certification, please write to the above address.

ANESTHESIOLOGY

March 11-13—**Anesthesia for High Risk Mother.** UCSF at Golden Gate Holiday Inn, San Francisco. Friday-Sunday.

March 20-25—**9th Annual Winter Meeting of the Anesthesiology Education Foundation.** UCLA at Sierra Nevada Inn, Mammoth Lakes. Sunday-Friday.

May 1-7—**Biennial Western Conference on Anesthesiology.** Wailea Beach Hotel, Maui. One week. 25 hrs. Contact: Murray G. Atnikov, MD, Sec-Treas., Biennial Western Conf. on Anesthesiology, Ste. M2A, Broadway Plaza, 601 W. Broadway, Vancouver, BC V5Z 4C2.

CANCER

February 15-18—**Clinical Hematology and Oncology.** See Medicine, February 15-18.

March 5-6—**Hyperthermia and Radiation Therapy in the Treatment of Cancer—18th Annual Cancer Symposium.** West Coast Cancer Foundation at Sheraton Palace, San Francisco. Saturday-Sunday. 12 hrs. \$115 before Feb. 1; \$140, thereafter. Contact: WCCF, 50 Francisco St., Suite 200, San Francisco 94133. (415) 981-4590.

March 9-11—**Current Approaches to Radiation Oncology, Biology and Physics.** UCSF at Fairmont, San Francisco. Wednesday-Friday.

April 9—**Oncology Update Symposium.** Northridge Hospital Medical Center at Biltmore Hotel, Los Angeles. Saturday. 8 hrs. \$125. Contact: Sandra Rozzen, Northridge Hosp. Med. Ctr., 18300 Roscoe Blvd., Northridge 91328. (213) 885-5311.

April 22-24—**The Primary Care Physician and Cancer: Prevention, Early Detection and Treatment.** UCSD at Vacation Village, San Diego. Friday-Sunday. 20 hrs. \$275. Contact: Howard D. Groveman, MD, UCSD Sch. of Med. (m-022), La Jolla 92093. (619) 452-4613.

June 23-28—**Head and Neck Cancer: Current Ablation and Reconstruction Techniques.** UCD. Thursday-Tuesday.

EMERGENCY MEDICINE

February 20-25—**Winter Sports Injuries: Skiing Injuries—An In-Depth Course.** UCD at Hyatt Lake Tahoe, Incline Village, NV. Sunday-Friday. 24 hrs. Physicians, \$395; Residents, \$200.

March 13-18—**Fourth Annual Mammoth Mountain Emergency Medicine Ski Conference.** UCI and Orange Co. Emergency

Dept. Nurses Assn. at Mammoth Lakes. Sunday-Friday. 23 hrs. \$325. Contact: Medical Conferences, Inc., P.O. Box 52-B, Newport Beach 92662. (714) 642-7080.

March 14-18—**Postgraduate Institute for Emergency Physicians—Symposium II.** UCSD. Monday-Friday. 33 hrs. \$425.

April 22-24—**Advanced Cardiac Life Support Workshops.** Emergency Medical Associates at Ralph K. Davies Medical Center, San Francisco. Friday-Sunday. Contact: EMA, 2310 Mason St., San Francisco 94133. (415) 956-5900.

May 2-6—**Postgraduate Institute for Emergency Physicians—Symposium I.** UCSD at Hilton, San Diego. Monday-Friday. 33 hrs. \$425.

May 28-30—**Wilderness and Emergency Medicine White Water Trip.** Mercy Medical Center at Klamath Scott River Canyon.

(Continued on Page 181)

KEY TO ABBREVIATIONS

- CMA: California Medical Association
Contact: Continuing Medical Education, California Medical Association, 731 Market Street, San Francisco 94103. (415) 777-2000.
- DREW: Charles R. Drew Postgraduate Medical School
Contact: Duane Dillman, PhD, Director, Office of Continuing Education, Charles R. Drew Postgraduate Medical School, 1621 East 120th Street, Los Angeles 90059. (213) 603-3091.
- LLU: Loma Linda University
Contact: Varner J. Johns, Jr., MD, Associate Dean for Continuing Medical Education, Loma Linda University School of Medicine, Loma Linda 92354. (714) 796-7311, ext. 2400.
- PMC: Pacific Medical Center
Contact: Continuing Education, Pacific Medical Center, P.O. Box 7999, San Francisco 94120. (415) 563-4321, ext. 2761.
- STAN: Stanford University
Contact: Edward Rubenstein, MD, Associate Dean for Postgraduate Education, Stanford University School of Medicine, 300 Pasteur Drive, Stanford 94305. (415) 497-5594.
- UCD: University of California, Davis
Contact: Ruth Feryok, Director, Office of Continuing Medical Education, University of California, Davis, School of Medicine, Davis 95616. (916) 752-0328.
- UCI: University of California, Irvine
Contact: E. R. Jennings, MD, Assistant Dean, University of California, Irvine, California College of Medicine, c/o UCI/CME Program, Memorial Hospital Medical Center 2801 Atlantic Ave., Long Beach 90801. (213) 595-3837.
- UCLA: University of California, Los Angeles
Contact: Martin D. Shickman, MD, Director, Continuing Education in Medicine and the Health Sciences, P.O. Box 24902, UCLA, Los Angeles 90024. (213) 825-7241.
- UCSD: University of California, San Diego
Contact: Office of Continuing Medical Education, University of California, San Diego, School of Medicine (M-017), La Jolla 92093. (619) 452-3708.
- UCSF: University of California, San Francisco
Contact: David S. Gullion, MD, Director, Extended Programs in Medical Education, School of Medicine, University of California, San Francisco 94143. (415) 666-4251.
- USC: University of Southern California
Contact: Phil R. Manning, MD, Associate Dean, Postgraduate Division, University of Southern California School of Medicine, 2025 Zonal Avenue, Los Angeles 90033. (213) 224-7051.

Saturday-Monday. 12 hrs. \$275. Contact: CME Dept., Mercy Medical Center, Clairmont Heights, Redding 96001. (916) 243-2121.

June 13-17—**Postgraduate Institute for Emergency Physicians—Symposium III.** UCSD at Hanalei Hotel, Mission Valley, San Diego. Monday-Friday. 33 hrs. \$425.

June 19-22—**Marin Medicine.** UCD at Hyatt Del Monte, Monterey. Sunday-Wednesday.

July 22-24—**Advanced Cardiac Life Support Workshop.** Emergency Medical Associates at Ralph K. Davies Medical Center, San Francisco. Friday-Sunday. Contact: EMA, 2310 Mason St., San Francisco 94133. (415) 956-5900.

June 27-July 1—**Topics in Emergency Medicine.** UCSF at Sheraton at Fisherman's Wharf, San Francisco. Monday-Friday.

July 2-4—**Wilderness and Emergency Medicine White Water Trip.** Mercy Medical Center, Redding at Klamath Scott River Canyon. Saturday-Monday. 12 hrs. \$275. Contact: CME Dept., Mercy Medical Center, Clairmont Heights, Redding 96001. (916) 243-2121.

MEDICINE

February 15-18—**Clinical Hematology and Oncology: 1983.** Scripps Clinic and Research Foundation at Sheraton Harbor Island, San Diego. Tuesday-Friday. 31 hrs. \$390. Contact: Dianne Tisue, Dept. of Academic Affairs, Scripps Clinic and Research Fndn., 10666 N. Torrey Pines Rd., La Jolla 92037. (619) 455-9100.

February 17-19—**Therapeutic and Diagnostic Uses of the Cardiac Catheter.** American College of Cardiology at Bonaventure Hotel, Los Angeles. Thursday-Saturday. Contact: Extramural Prog. Dept., ACC, 9111 Old Georgetown Rd., Bethesda, MD 20814.

February 18-19—**Cardiac Rehabilitation.** International Medical Education Corp. at Marriott, Anaheim. Friday-Saturday. 13 hrs. \$260. Contact: IMEC, 64 Inverness Dr. E., Englewood, CO 80112. (800) 525-8651.

February 19—**Infectious Disease: A Practical Approach.** UCD at Sacramento Inn, Sacramento. Saturday. 6 hrs. \$85.

February 21-23—**Office Endocrinology 1983.** UCSF at Golden Gate Holiday Inn, San Francisco. Monday-Wednesday.

February 22-28—**Cardiology Update.** Straub Clinic and Institute for Medical Studies. Hilton Hawaiian Village, Honolulu and Maui Marriott, Maui. One week. 19 hrs. \$350. Contact: Kim Stroich, IMS, 14761 Franklin St., Suite A, Tustin 92680. (714) 832-2650.

February 23-27—**Neurological Problems.** UCLA and Federation of Western Neurological Societies at UCLA and Sheraton-Miramar, Santa Monica. Wednesday-Sunday. 18 hrs.

February 25-27—**Clinical Management of Coronary Disease and Dual-Mode Exercise Testing.** International Medical Education Corp. at Dunes Hotel, Las Vegas. Friday-Sunday. 13 hrs. \$260. Contact: IMEC, 64 Inverness Dr. E., Englewood, CO 80112. (800) 525-8651.

February 26-27—**Immunology.** STAN. Saturday-Sunday. 13 hrs. \$250.

February 26-27—**Basic Neuroscience.** STAN. Saturday-Sunday. 12 hrs. \$250.

February 27-March 2—**Basic Cardiology for the Practicing Physician.** UCSF at Hyatt, Lake Tahoe. Sunday-Wednesday. 15 hrs. \$225.

March 4—**9th Annual Diabetes Conference.** UCD at Red Lion Motor Inn, Sacramento. Friday. 7 hrs.

March 4-8—**Topics in Internal Medicine.** UCSD at Town and Country Hotel, San Diego. Friday-Tuesday. 40 hrs. \$430.

March 6-9—**Dermatology Consultants' Course.** UCSF at Ahwahnee Hotel, Yosemite. Sunday-Wednesday.

March 9—**Therapy of Ischemic Heart Disease.** LLU. Wednesday.

March 10-11—**Neurosciences Symposium III.** Sutter Community Hospitals at Red Lion Motor Inn, Sacramento. Friday-Saturday. 14 hrs. Contact: Janette Wackerly, Sutter Gen. Hosp., 2820 L St., Sacramento 95816. (916) 454-2222, ext. 1430.

March 12-18—**ECG Interpretation and Arrhythmia Management.** International Medical Education Corp. at Sheraton, Maui. Saturday-Friday. 16 hrs. Contact: IMEC, 64 Inverness Dr. E., Englewood, CO 80112. (800) 525-8651.

March 14-18—**Allergy and Dermatology.** Symposium Maui, Inc.; American Academy of Family Physicians, Hawaii Chap.; Hawaii Medical Assn. at Royal Lahaina Resort, Kaanapali, Maui. Monday-Friday. 22 hrs. Contact: Joe Harrison, MD, Symposium Maui, Inc., P.O. Box 10185, Lahaina, Maui 96761.

March 16-23—**Gastroenterology.** Society for Continuing Medical Education and Cleveland Clinic at Regent Hotel, Honolulu. One week. 24 hrs. \$250. Contact: Erwin Witkin, MD, Soc. for CME, 6609 Reisterstown Rd., Ste 208, Baltimore, MD 21215. (301) 358-1540.

March 18—**Nora Eccles Harrison Diabetes and Nutrition Update: Heart Disease, Kidney Disease and Pregnancy.** UCD. Friday. 6 hrs. \$25.

March 18-20—**ECG Interpretation and Arrhythmia Management.** International Medical Education Corp. at Sheraton at the Wharf, San Francisco. Friday-Sunday. 13 hrs. Contact: IMEC, 64 Inverness Dr. E., Englewood, CO 80112. (800) 525-8651.

March 19-20—**MKSAP VI Review Course—Internal Medicine Review Part II.** American College of Physicians and UCLA at UCLA. Saturday-Sunday. 12 hours. \$160. Contact: UCLA.

March 19-26—**Advances in Internal Medicine.** University of Washington School of Medicine at Royal Lahaina, Maui. One week. Contact: University of Washington School of Medicine, Div. of CME, SC-50, Seattle 98195. (206) 543-1050.

March 25-27—**Arrhythmia and Cardiac Ischemia: Diagnosis and Management.** International Medical Education Corp. at Sahara, Las Vegas. Friday-Sunday. 13 hrs. \$260. Contact: IMEC, 64 Inverness Dr. E., Englewood, CO 80112. (800) 525-8651.

March 26—**Occupational Lung Health Conference.** American Lung Association of Los Angeles County at University Hotel, Los Angeles. Friday. 6 hrs. Contact: Gerrie Kilburn, RN, (213) 484-9300.

March 26-April 2—**Vascular Disease.** Univ. of Washington School of Medicine at Royal Lahaina, Maui. One week. Contact: U/W Sch. of Med., Div. of CME, SC-50, Seattle 98195. (206) 543-1050.

March 30-April 1—**Practical Dermatology.** STAN. Wednesday-Friday. Contact: Paul H. Jacobs, MD, Dept. of Dermatology, Stanford University Medical School, Stanford 94305. (415) 497-6101.

April 8-9—**Immunology for the Clinician With Robert Good.** UCD at The Red Lion Inn, Sacramento. Friday-Saturday. 10 hrs.

April 10-13—**Dermatology for the Clinician: Annual Yosemite Symposium.** UCD at Ahwahnee Hotel, Yosemite. Sunday-Wednesday.

April 11-14—**American College of Physicians—64th Annual Session.** Moscone Center, San Francisco. Monday-Thursday. Contact: ACP, 4200 Pine St., Philadelphia 19104. (215) 243-1200.

April 11-14—**Renal, Acid-Base and Electrolyte Disorders for the Practicing Physician.** LLU at Mauna Kea Beach Hotel, Kamuela. Monday-Thursday. 16 hrs.

April 13—**24th Annual Physicians' Symposium—Atherosclerosis: Dilate, Operate, Infuse?** American Heart Association, Santa Clara County Chapter at Le Baron Hotel, San Jose. Wednesday. 6 hrs. Members, \$40; Nonmembers, \$50. Contact: American Heart Association, Santa Clara County Chapter, 3003 Moorpark Ave., San Jose 94128. (408) 247-8555.

April 15-17—**Ambulatory Electrocardiography: Clinical Applications, Methodology, and Interpretation.** International Medical Education Corp. at Hyatt, Anaheim. Friday-Sunday. 13 hrs. \$260. Contact: IMEC, 64 Inverness Dr. E., Englewood, CO 80112. (800) 525-8651.

April 16-17—**The Pneumonias.** UCSF in Monterey. Saturday-Sunday.

April 23—**Outpatient Management of Infections: The Role of Antimicrobial Agents.** Alta Bates Hospital, Berkeley. Friday. 6 hrs. Physicians, \$75; Residents, \$50. Contact: Medical Education Dept., Alta Bates Hospital, 3001 Colby St. at Ashby, Berkeley 94705. (415) 540-1420.

April 24-29—**American Academy of Neurology.** Town and Country, San Diego. Sunday-Friday. Contact: AAN, 2221 University Ave., S.E., Minneapolis 55414.

May 5-6—**Infectious Diseases Symposium.** Sutter Community Hospitals at Red Lion Inn, Sacramento. Thursday-Friday. 13 hrs. Contact: Office of Cont. Med. Ed., Sutter Community Hospitals, 28th and L Sts., Sacramento 95816.

May 11—**Osteoarthritis—Diagnosis and Management.** LLU. Wednesday. 4 hrs.

May 13-15—**Ambulatory Electrocardiography: Clinical Applications, Methodology, and Interpretation.** International Medical Education Corp. at Sahara, Las Vegas. Friday-Sunday. 13 hrs. \$260. Contact: IMEC, 64 Inverness Dr. E., Englewood, CO 80112. (800) 525-8651.

May 13-15—**ECG Interpretation and Arrhythmia Management.** International Medical Education Corp. at Sahara, Reno. Friday-Sunday. 13 hrs. \$260. Contact: IMEC, 64 Inverness Dr. E., Englewood, CA 80112. (800) 525-8651.

May 16-20—**Advances in Internal Medicine.** UCSF at Golden Gateway Holiday Inn, San Francisco. Monday-Friday.

May 18—**Thyroid '83.** The Hospital of the Good Samaritan at Hyatt Regency Hotel, Los Angeles. Wednesday. 6 hrs. Contact: Bonnie VanWaardenburg, Coordinator of Symposia, 616 South Witmer St., Los Angeles 90017. (213) 977-2345.

May 20-22—**New Concepts in Clinical Electrocardiography.** American College of Cardiology at Sinai Medical Center, Los Angeles. Friday-Sunday. Contact: Extramural Programs Dept., ACC, 9111 Old Georgetown Rd., Bethesda, MD 20814.

June 8—**Hiatal Hernia and Esophageal Reflux—Modern Therapy.** LLU. Wednesday.

June 11—**California Society of Internal Medicine Annual Meeting** at Newporter Inn, Newport Beach. Saturday. Contact: California Society of Internal Medicine, 703 Market St., 1412 Central Towers, San Francisco 94103. (415) 362-1548.

June 12-15—**Advanced Clinical Echocardiography—1983: M-Mode, 2-Dimensional and Pulse Doppler Techniques.** American College of Cardiology at Sheraton Harbor Island Hotel, San Diego. Sunday-Wednesday. Contact: Extramural Programs Dept., ACC, 9111 Old Georgetown Rd., Bethesda, MD 20814.

June 13-17—**Advances in Internal Medicine.** UCSF. Monday-Friday.

June 24-26—**Clinical Management of Coronary Disease and Dual-Mode Exercise Testing.** International Medical Education Corporation at Islandia Hyatt, San Diego. Friday-Sunday.

13 hrs. \$260. Contact: IMEC, 64 Inverness Dr. E., Englewood, CO 80112. (800) 525-8651.

July 9-10—**MKSAP VI Review Course—Internal Medicine Review Part III.** American College of Physicians and UCLA at UCLA. Saturday-Sunday. 12 hrs. \$160.

July 15-17—**Arrhythmias and Cardiac Ischemia: Diagnosis and Management.** International Medical Education Corporation at Cal-Neva Hotel, Lake Tahoe. Friday-Sunday. 13 hrs. \$260. Contact: IMEC, 64 Inverness Dr. E., Englewood, CO 80112. (800) 525-8651.

July 29-31—**Clinical Management of Coronary Disease and Dual-Mode Exercise Testing.** International Medical Education Corporation at Sheraton at the Wharf, San Francisco. Friday-Sunday. 13 hrs. \$260. Contact: IMEC, 64 Inverness Dr. E., Englewood, CO 80112. (800) 525-8651.

July 31-August 3—**Rheumatology for the Clinician.** UCD at Hyatt Del Monte, Monterey. Sunday-Wednesday.

OBSTETRICS AND GYNECOLOGY

February 25-26—**2nd Annual Seminar in Endocrinology, Gynecologic Oncology, and Maternal-Fetal Medicine.** Riverside-San Bernardino Obstetrical and Gynecological Society at Spa Hotel, Palm Springs. Friday-Saturday. \$90. Contact: C. Arthur Anderson, MD, 355 Terracina Blvd., Redlands 92373.

March 12-19—**Office Gynecology.** Univ. of Washington School of Medicine at Sheraton Waikoloa, Kona. One week. Contact: U/W Sch. of Med., Div. of CME, SC-50, Seattle 98195. (206) 543-1050.

March 20-23—**OB/GYN for the Practicing Physician.** UCSF at Ahwahnee Hotel, Yosemite. Sunday-Wednesday.

March 28-April 1—**OB/GYN Update 1983.** University of Hawaii School of Medicine at Kona Surf Hotel, Hawaii. Monday-Friday. 24 hrs. \$300. Contact: Dee Chang, 1319 Punahou St., Room 816, Honolulu 96826. (808) 947-8573.

April 18-20—**Fifth Annual Orange County OB/GYN Congress.** Orange County Obstetrical and Gynecological Society at Sheraton, Newport Beach. Monday-Wednesday. 15 hrs. \$275. Contact: Orange County OB/GYN Soc., P.O. Box 1297, Orange 92668.

April 22-23—**28th Annual T. Hart Baker, MD OB/GYN Symposium.** Southern California Permanente Medical Group at The Bonaventure Hotel, Los Angeles. Friday-Saturday. Contact: Lilia M. Guerrero, Symposium Coordinator, SCPMG, Dept. of Education and Research, 4747 Sunset, 4th Floor, Los Angeles 90027. (213) 667-4241.

May 16-18—**Recent Advances in Obstetrics and Gynecology: 6th Annual Symposium.** UCSD and San Diego Reproductive Medicine Research and Education Foundation at Vacation Village, San Diego. Monday-Wednesday. \$275. Contact: Recent Advances in OB/GYN, P.O. Box 9494, San Diego 92109. (619) 272-3126.

June 1-4—**Controversies in Obstetrics and Gynecology.** Memorial Hospital Medical Center at Silverado Country Club, Napa Valley. Wednesday-Saturday. 20 hrs. Contact: Asst. Dir., Center for Health Ed., 2801 Atlantic Ave., Long Beach 90801. (213) 595-3811.

PEDIATRICS

February 17-19—**Pediatric Urology.** See Surgery, February 17-19.

February 23-March 1—**Adolescent/Young Adult Medicine.** Hurley Medical Center at Wailea Beach Hotel, Maui. One week. 20 hrs. Contact: Hurley Med Ctr., Dept. of Cont. Med. Ed., One Hurley Plaza, Flint, MI 48504. (313) 766-0142.

February 28-March 3—**Problems of the Contemporary Adolescent.** University of Hawaii School of Medicine at Kapio-

Iani Children's Medical Center, Honolulu. Monday-Thursday. 12 hrs. \$125. Contact: Dee Chang, 1319 Punahou St., Room 816, Honolulu 96826. (808) 947-8573.

March 3-5—**Advances in Pediatric Infectious Diseases.** Children's Hospital Medical Center of Northern Calif. at Sahara Hotel, Lake Tahoe. Thursday-Saturday. Contact: Gretchen Hayes-Dodd, Med. Staff Office, CHMC, 51st and Grove Sts., Oakland 94609. (415) 428-3334.

March 10-13—**Combined Southern California Pediatric Postgraduate Meeting.** Calif. Chap. 2, American Academy of Pediatrics, at Hilton Riviera, Palm Springs. Thursday-Sunday. Contact: Eve Black, P.O. Box 2134, Inglewood 90305. (213) 757-1198.

March 19-26—**Updates in Pediatrics: An Epic Medical Expedition.** American Institute of Primary Care Medicine and Univ. of Arizona College of Medicine at Maui. One week. 24 hrs. Contact: Richard Paris, MD, P.O. Box 209, Sun Valley, ID 83353.

April 8-9—**Pediatric Immunology.** UCD at Red Lion Inn, Sacramento. Friday-Saturday. 10 hrs.

April 20-22—**8th Annual Symposium—Care of the Sick Newborn.** Memorial Hospital Medical Center-UCI Center for Health Education, Long Beach. Wednesday-Friday. 17 hrs. Contact: Asst. Dir., Ctr. for Health Ed., 2801 Atlantic Ave., Long Beach 90801. (213) 595-3811.

May 12-14—**17th Annual Advances in Pediatrics.** UCSF at Mark Hopkins Hotel, San Francisco. Thursday-Saturday.

May 18—**Los Angeles Pediatric Society—Annual Spring Meeting.** Wednesday. Contact: Eve Black, Exec. Sec., P.O. Box 2022, Inglewood 90305. (213) 757-1198.

May 28-30—**Annual Spring Meeting.** California Chapters, American Academy of Pediatrics at Hyatt Del Monte, Monterey. Saturday-Monday. Contact: Beverly Busher, No. California Chapter, AAP, 422 Alexander Ave., Larkspur 94939. (415) 924-9613.

July 14-16—**Practical Aspects of Adolescent Health Care.** UCSD at Islandia Hyatt Hotel, San Diego. Thursday-Saturday. Contact: Marianne Felice, MD, UCSD. (619) 294-3601.

PSYCHIATRY

February 23-24—**Western Region Courses in Clinical Neurosciences.** UCLA, Federation of Western Societies of Neurological Science and the Los Angeles Society of Neurology and Psychiatry at Miramar Sheraton Hotel, Santa Monica. Wednesday-Thursday. 6 hrs. One day, \$100; Two days \$125. Contact: UCLA.

February 24-27—**Federation of Western Societies of Neurological Science Meeting.** UCLA, Federation of Western Sciences of Neurological Science and the Los Angeles Society of Neurology and Psychiatry. Thursday-Sunday. 15 hrs. \$250. Contact: UCLA.

February 26—**Sleep Disorders: Advances in Diagnosis and Treatment.** UCLA and California State Board of Registered Nursing at UCLA. Saturday. 7 hrs. \$95.

February 26-27—**Beyond the Relaxation Response: Self-Regulation Mechanisms.** UCLA. Saturday-Sunday. 14 hrs. \$200.

February 26-27—**Biobehavioral Science for Psychiatrists.** STAN. Saturday-Sunday. 11 hrs. \$250.

February 26-27—**Emotions in Health and Illness.** UCSF at Golden Gateway Holiday Inn, San Francisco. Saturday-Sunday.

March 3-4—**Psychoneuroimmunology.** LLU. Thursday-Friday. 13 hrs.

March 19-20—**Countertransference in Psychotherapy.** UCLA. Saturday-Sunday. \$165.

March 25-27—**General Psychiatry Board Review.** UCSF. Friday-Sunday.

May 21-22—**Freud-Jung Symposium** at UCSF. Saturday-Sunday.

RADIOLOGY AND PATHOLOGY

February 23-25—**New Imaging Modalities in Radiology.** Memorial Hospital Medical Center at Hilton Riviera, Palm Springs. Wednesday-Friday. 18 hrs. Contact: Asst. Dir., Ctr. for Health Ed., 2801 Atlantic Ave., Long Beach 90801.

March 9-11—**Sierra Radiology Conference.** Sacramento Radiology Research and Education Foundation at North Lake Tahoe. Wednesday-Friday. 18 hrs. \$280. Contact: Arthur B. Dublin, MD, Prog. Dir., Sacramento Radiology Research and Education Fndn., P.O. Box 161112, Sacramento 95816.

March 11-13—**2nd Annual Ultrasound Update (Abdominal and Obstetrical).** Memorial Hospital of Long Beach and Institute for Medical Studies at Riviera Hotel, Las Vegas. Friday-Sunday. 16 hrs. \$300. Contact: Kim Stroich, IMS, 14761 Franklin Ave., Suite A, Tustin 92680. (714) 832-2650.

March 12-13—**Uroradiology.** UCSF at Fairmont Hotel, San Francisco. Saturday-Sunday.

March 14-18—**Diagnostic Radiology.** UCSF. Monday-Friday. 33 hrs. \$400.

March 14-18—**4th Midwinter Diagnostic Radiology Conference on Imaging Modalities in the Chest and Abdomen.** Loyola Univ. at Kapala Bay Hotel, Maui. Monday-Friday. 20 hrs. \$325. Contact: L. Gunzburger, PhD, Div. of Cont. Med. Ed., Loyola Univ. Med. Ctr., 2160 S. 1st Ave., Maywood, IL 60153. (312) 531-3236.

March 21-25—**Obstetric and Gynecologic Pathology.** American Society of Clinical Pathologists at San Diego. Monday-Friday. 28 hrs. \$550/\$650. Contact: Marian Macdonald, ASCP, 2100 W. Harrison St., Chicago 60612. (312) 738-1336.

March 23-25—**Current Concepts in Surgical Pathology.** STAN. Wednesday-Friday. 21 hrs. \$400.

March 25-26—**Cellular and Molecular Endocrinology.** UC-Riverside and UCLA at UC-Riverside. Friday-Saturday. Contact: Dr. Anthony W. Norman, Dept. of Biochemistry, Univ. of Calif., Riverside 92521. (714) 787-4777.

April 13-15—**Radiology of the Emergency Patient.** UCI at Century Plaza, Los Angeles. Wednesday-Friday. 18 hrs. \$295. Contact: Phyllis Roy, UCIMC-Radiology, #103, 101 City Dr. So., Orange 92668. (714) 634-6579.

April 15-17—**B-Scan Ultrasonography: Update.** UCSF at Fairmont Hotel, San Francisco. Friday-Sunday. \$250.

July 31-August 5—**21st Annual Postgraduate Course in Dermal Pathology.** UCI at Newporter Resort, Newport Beach. Sunday-Friday. 40 hrs. Contact: Asst. Dir., Center for Health Ed., 2801 Atlantic Ave., Long Beach 90801. (213) 595-3823.

SURGERY

February 17-19—**Pediatric Urology.** American Urological Assn. at Hilton, San Diego. Thursday-Saturday. 16 hrs. Contact: Alice Henderson, Office of Ed., AUA, P.O. Box 25147, Houston TX 77265. (713) 790-6070.

February 19—**The Dimensions of Cardiac Surgery.** Heart Institute of the Desert, Eisenhower Medical Center, Rancho Mirage. Saturday. 1½ hrs. Contact: Heart Inst. of the Desert, 39000 Bob Hope Dr., Rancho Mirage 92270. (619) 568-2900.

February 19-26—**Updates in Trauma: An Epic Medical Expedition.** American Inst. of Primary Care Medicine and Univ. of Arizona College of Medicine at Maui. One week. 24 hrs. Contact: Richard Paris, MD, P.O. Box 209, Sun Valley, ID 83353.

ZORprin®

ZERO ORDER RELEASE | ASPIRIN

DESCRIPTION: Each capsule-shaped tablet contains 800 mg of aspirin, formulated in a special tablet matrix to control the release rate of aspirin after ingestion. Zero order release means, that, the in vitro release of aspirin from the tablet matrix is linear and independent of the concentration of drug. ■ **INDICATIONS & USAGE:** ZORPRIN is indicated for the treatment of rheumatoid arthritis, osteoarthritis and bursitis. The release of aspirin from the tablet matrix is zero order, but is pH dependent. In an in vitro acid media, which is similar to that found in the stomach and first part of the duodenum, the release rate of the drug is very slow. However, in an in vitro near neutral to alkaline media, similar to that found in the small intestine, the majority (90%) of the drug is released from the tablet matrix. Because ZORPRIN is designed to release aspirin in a media similar to that found in the small intestine and at a rather constant rate, it may be tolerated by some patients intolerant to aspirin by reason of gastric irritation. ■ **CONTRAINDICATIONS:** Contraindicated in patients known to be allergic to salicylates or individuals with advanced chronic renal insufficiency. ■ **WARNINGS: Use in Pregnancy:** Regular aspirin interferes with maternal and infant blood clotting and lengthens the duration of pregnancy and parturition. Aspirin has produced teratogenic effects in animals and increases the incidence of stillbirths and neonatal deaths in humans. The safety of ZORPRIN during pregnancy has not been established. Use of this drug requires that the physician evaluate the potential benefits of the drug against any possible hazard to the mother and child. ■ **PRECAUTIONS:** Appropriate precautions should be taken in prescribing ZORPRIN for patients who are known to be sensitive to aspirin or salicylates. Particular care should be used when prescribing this medication for patients with erosive gastritis or peptic ulcer. As with all salicylate drugs, caution should be urged in using ZORPRIN for those patients with bleeding tendencies or those on anticoagulant drugs. ■ **ADVERSE REACTIONS: Hematologic** — Aspirin interferes with blood clotting. Patients with a history of blood coagulation defects, or receiving anticoagulant drugs or with severe anemia should avoid ZORPRIN. Aspirin used chronically may cause a persistent iron deficiency anemia. ● **Gastrointestinal** — Aspirin may potentiate peptic ulcer, cause stomach distress, or heartburn. Aspirin can cause an increase in occult bleeding and in some patients massive gastrointestinal bleeding. However, the greatest release of active drug from ZORPRIN is designed to occur in the small intestine over a period of time. This has resulted in less symptomatic gastrointestinal side effects. Patients who have had adverse G.I. reactions with other aspirin preparations have tolerated ZORPRIN. ● **Allergic** — Allergic and anaphylactic reactions have been noted when hypersensitive individuals have taken aspirin. The most common allergic reaction to aspirin is the induction of bronchospasm with asthma-like symptoms. Other reactions are hives, rash, angioedema, as well as rhinitis and nasal polyposis. Fatal anaphylactic shock while not common has been reported. ● **Central Nervous System** — Taken in overdoses, aspirin produces stimulation which may be manifested by tinnitus. Following initial stimulation, depression of the central nervous system may be noted. ● **Renal** — Aspirin may rarely cause an increase in the severity of chronic kidney disease. ● **Hepatic** — High doses of aspirin have been reported to produce reversible hepatic dysfunction. ● **Drug Interactions** — Aspirin may interfere with some anticoagulant and antidiabetic drugs. Uric acid-lowering drugs, which are uricosurics, are antagonized by the concomitant use of aspirin. Nonsteroidal anti-inflammatory drugs may be competitively displaced from their albumin binding sites by aspirin. This effect will ameliorate the clinical efficacy of both drugs. Also, the gastrointestinal inflammatory potential of nonsteroidal anti-inflammatory drugs may be potentiated by aspirin. Alcohol produces a synergistic effect with aspirin in causing gastrointestinal bleeding. ■ **OVERDOSAGE:** Overdosage, if it occurs would produce the usual symptoms of salicylism: tinnitus, vertigo, headache, confusion, drowsiness, sweating, hyperventilation, vomiting or diarrhea. Treatment: For mild intoxication, emptying the stomach with an emetic, or gastric lavage with 5% sodium bicarbonate. Individuals suffering from severe intoxication should, in addition, have forced diuresis by intravenous infusions of saline and sodium bicarbonate or sodium lactate, dextrose solution. In extreme cases, hemodialysis or peritoneal dialysis may be required. ■ **DOSAGE & ADMINISTRATION:** In order to achieve a zero-order release, the tablets of ZORPRIN should be swallowed whole. Breaking the tablets or disrupting the structure will alter the release profile of the drug. ● **Adult Dosage:** For mild to moderate pain associated with rheumatoid arthritis and osteoarthritis as well as bursitis, the recommended initial dose of ZORPRIN is 1600 mg (2-800 mg tablets) twice a day. Because of ZORPRIN prolonged release of aspirin into the bloodstream, the tablets may be taken as a b.i.d. dose. Further upward or downward adjustment of the dosage should be determined by the physician, based upon the patient's response and needs. ● **Dosage for Juvenile Rheumatoid Arthritis:** ZORPRIN is a zero order release aspirin and no studies have been conducted in children with this formulation. The use of ZORPRIN as therapy requires that the child is able to swallow the tablet whole without chewing or crushing, consequently, ZORPRIN is not recommended for children below the age of 5 years. ● **How Supplied:** Bottles of 100 Tablets — NDC 0524-0057-01



Boots Pharmaceuticals, Inc.

6540 LINE AVENUE, P.O. BOX 6750
SHREVEPORT, LOUISIANA 71106-9989

Pioneers in medicine for the family

(Continued from Page 191)

February 23-24—**Neurological Problems.** Federation of Western Neurological Societies and UCLA at UCLA. Wednesday-Thursday. Contact: UCLA.

March 7-11—**Surgical Forum.** Soc. of Graduate Surgeons of the Los Angeles Co./USC Med. Ctr. at Ambassador Hotel, Los Angeles. Monday-Friday. 31 hrs. \$350. Contact: Dir. of Med. Ed., Soc. of Graduate Surgeons, 5820 Wilshire Blvd., #500, Los Angeles 90036. (213) 937-5514.

March 9-10—**American Orthopaedic Foot Society.** Anaheim. Wednesday-Thursday. 12½ hrs. Contact: Kenneth A. Johnson, MD, Dept. of Orthopedics, Mayo Clinic, Rochester, MN 55905. (507) 284-2778.

March 10-13—**American Society for Head and Neck Surgery 15th Anniversary Meeting** at The Canyon Hotel, Palm Springs. Tuesday-Friday. 16¼ hrs. \$350. Contact: ASHNS, Stanford Univ. Med. Ctr., R-135, Stanford 94305. (415) 497-5828.

March 10-15—**American Academy of Orthopaedic Surgeons.** Convention Center, Anaheim. Thursday-Tuesday. Contact: AAOS, 444 N. Michigan Ave., Chicago 60611.

March 12—**Women vs Men—Long-Term Results of Myocardial Revascularization.** Heart Institute of the Desert, Eisenhower Medical Center, Rancho Mirage. Saturday. 1½ hrs. Contact: Heart Inst. of the Desert, 39000 Bob Hope Dr., Rancho Mirage 92270. (619) 568-2900.

March 14-18—**Sports Medicine.** Univ. of Hawaii at Princess Kaiulani Hotel, Waikiki, Honolulu. Monday-Friday. 18 hrs. \$250. Contact: Ms. Joy Lewis, Box CEW-CCECS, 2530 Dole St., Honolulu 96822. (808) 948-8244.

March 17-19—**Gynecologic Surgery With Emphasis on Gynecologic Urology.** Memorial Hospital Medical Ctr. at Hilton Riviera, Palm Springs. Thursday-Saturday. 15 hrs. Contact: Asst. Dir., Ctr. for Health Ed., 2801 Atlantic Ave., Long Beach 90801.

March 19-20—**Ophthalmology Update on Basic Sciences for the Clinician.** Update: Fndn. for Systematic Postgraduate Education in Ophthalmology, UCD, PMC, UCSF, STAN at San Franciscan Hotel, San Francisco. Saturday-Sunday. Contact: Update, 3910 San Hill Rd., Woodside 94062. (415) 563-4321, ext. 2763.

March 19-23—**20th Annual Seminar on Controversial Areas in Surgery.** UCLA at Palm Springs. Saturday-Wednesday.

March 23-25—**Diseases of the Urinary Tract.** STAN at Rickey's Hyatt, Palo Alto. Wednesday-Friday. 16 hrs. \$225.

March 23-27—**11th Annual Symposium on Vascular Surgery.** UCLA at Palm Springs. Wednesday-Sunday.

March 26—**Complications of Myocardial Infarction Surgical Management.** Heart Institute of the Desert, Eisenhower Medical Center, Rancho Mirage. Saturday. 1½ hrs. Contact: Heart Inst. of the Desert, 39000 Bob Hope Dr., Rancho Mirage 92270. (619) 568-2900.

April 9-16—**Cardiovascular Medicine and Surgery: An Advanced Course.** See Medicine, April 9-16.

April 15-16—**American Association of Clinical Urologists.** Hilton, Las Vegas. Friday-Saturday. Contact: AACU, 2017 Walnut St., Philadelphia 19117.

April 16—**Endoscopy for the General Surgeon** at Cedars-Sinai Medical Center, Los Angeles. Saturday. Contact: Cedars-Sinai Medical Center, Room 2049, P.O. Box 48750, Los Angeles 90048. (213) 855-5547.

April 17-21—**American Urological Association.** Convention Center, Las Vegas. Sunday-Thursday. 35 hrs. \$350, nonmembers. Contact: Richard J. Hannigan, Exec. Sec., AUA, 1120 N. Charles St., Baltimore, MD 21201. (301) 727-1100.

(Continued on Page 199)

Diet & Diabinese (chlorpropamide)

Tablets 100 mg and 250 mg

A proven regimen...
continue it with
confidence.

BRIEF SUMMARY

DIABINESE® (chlorpropamide) Tablets

Contraindications: Diabinese is not indicated in patients having juvenile or growth-onset diabetes mellitus, severe or unstable "brittle" diabetes, and diabetes complicated by ketosis and acidosis, diabetic coma, major surgery, severe infection, or severe trauma. Diabinese is contraindicated during pregnancy. Serious consideration should be given to the potential hazard of its use in women of childbearing age who may become pregnant.

Diabinese is contraindicated in patients with serious impairment of hepatic, renal, or thyroid function.

Precautions: Use chlorpropamide with caution with barbiturates, in patients with Addison's disease or in those ingesting: alcohol, antibacterial sulfonamides, thiazides, phenylbutazone, salicylates, probenecid, dicoumarol or MAO inhibitors. Adequate dietary intake should be assured in all patients using Diabinese.

Warnings: DIABINESE (CHLORPROPAMIDE) SHOULD NOT BE USED IN JUVENILE DIABETES OR IN DIABETES COMPLICATED BY ACIDOSIS, COMA, SEVERE INFECTION, MAJOR SURGICAL PROCEDURES, SEVERE TRAUMA, SEVERE DIARRHEA, NAUSEA AND VOMITING, ETC. HERE, INSULIN IS INDISPENSABLE.

HYPOGLYCEMIA, IF IT OCCURS, MAY BE PROLONGED. (SEE ADVERSE REACTIONS.) IN INSTANCES OF CONCOMITANT USE WITH INSULIN, PATIENTS SHOULD BE CAREFULLY MONITORED.

Adverse Reactions: Usually dose-related and generally respond to reduction or withdrawal of therapy. Generally transient and not of a serious nature and include anorexia, nausea, vomiting and gastrointestinal intolerance; weakness and paresthesias.

Certain untoward reactions associated with idiosyncrasy or hypersensitivity have occasionally occurred, including jaundice, skin eruptions rarely progressing to erythema multiforme and exfoliative dermatitis, and probably depression of formed elements of the blood. They occur characteristically during the first six weeks of therapy. With a few exceptions, these manifestations have been mild and readily reversible on the withdrawal of the drug. The more severe manifestations may require other therapeutic measures, including corticosteroid therapy. Diabinese should be discontinued promptly when the development of sensitivity is suspected.

Jaundice has been reported, and is usually promptly reversible on discontinuance of therapy. THE OCCURRENCE OF PROGRESSIVE ALKALINE PHOSPHATASE ELEVATION SHOULD SUGGEST THE POSSIBILITY OF INCIPIENT JAUNDICE AND CONSTITUTES AN INDICATION FOR WITHDRAWAL OF THE DRUG. Leukopenia, thrombocytopenia and mild anemia, which occur occasionally, are generally benign and revert to normal, following cessation of the drug.

Cases of aplastic anemia and agranulocytosis, generally similar to blood dyscrasias associated with other sulfonylureas, have been reported.

BECAUSE OF THE PROLONGED HYPOGLYCEMIC ACTION OF DIABINESE, PATIENTS WHO BECOME HYPOGLYCEMIC DURING THERAPY WITH THIS DRUG REQUIRE CLOSE SUPERVISION FOR A MINIMUM PERIOD OF 3 TO 5 DAYS, during which time frequent feedings or glucose administration are essential. The anorectic patient or the profoundly hypoglycemic patient should be hospitalized.

Rare cases of phototoxic reactions have been reported. Edema associated with hyponatremia has been infrequently reported. It is usually readily reversible when medication is discontinued.

Dosage: The total daily dosage is generally taken at a single time each morning with breakfast. Occasionally, cases of gastrointestinal intolerance may be relieved by dividing the daily dosage. A LOADING OR PRIMING DOSE IS NOT NECESSARY AND SHOULD NOT BE USED. The mild to moderately severe, middle-aged, stable diabetic should be started on 250 mg daily. Because the geriatric diabetic patient appears to be more sensitive to the hypoglycemic effect of sulfonylurea drugs, older patients should be started on smaller amounts of Diabinese, in the range of 100 to 125 mg daily.

After five to seven days following initiation of therapy, dosage may be adjusted upward or downward in increments of 50 to 125 mg at intervals of three to five days. PATIENTS WHO DO NOT RESPOND COMPLETELY TO 500 MG DAILY WILL USUALLY NOT RESPOND TO HIGHER DOSES. Maintenance doses above 750 mg daily should be avoided.

Supply: 100 mg and 250 mg, blue, 'D'-shaped, scored tablets.

More detailed professional information available on request.

Pfizer LABORATORIES DIVISION
PFIZER INC.

Leaders in Oral Diabetic Therapy

The Western Journal of Medicine

CLASSIFIED RATES

\$5.00 PER LINE

(Average six words per line)

FIVE LINE MINIMUM
BOX NUMBERS \$5.00 EXTRA

DISPLAY CLASSIFIED

\$50 PER COLUMN INCH

Three column page rate available on request

COLUMN WIDTH

1 column 2 1/8" • 2 columns 4 1/2" • 3 columns 7"

(Classified Advertising is payable in advance)

Please type or print advertising copy

DEADLINE

1st of Month before publication date

731 MARKET STREET

SAN FRANCISCO, CA 94103 • (415) 777-2000

Professional/
Executive
Signature
Loans
Up to
\$25,000

ENTIRELY
BY MAIL

NO PRE-PAY
PENALTY

Handled in the strictest
confidence through
unmarked mail. Attractive
rates. Quick response.
Write or call Mr. R. J.
Malcomb today.

**THE BANKERS
INVESTMENT COMPANY**
(213) 304-3049

Mr. R.J. Malcomb
BANKERS INVESTMENT COMPANY
P.O. Box 4602, Pasadena, CA 91101

Amount Requested _____

Name _____

Address _____

City _____ State _____ Zip _____

Lockdrawer WJ2/83

- April 21-24—**Wound Management Workshop.** Plastic Surgery Research Foundation at Hilton, San Diego. Thursday-Sunday. 20 hrs. Contact: Edith S. Bookstein, 7810 Lookout Dr., La Jolla 92037. (714) 454-3212.
- April 22-23—**14th Annual Postgraduate Seminar—Eyelids, Orbit and Lacrimal Apparatus.** Jules Stein Eye Institute, Los Angeles. Friday-Saturday. 16 hrs. Contact: Lu Hendricks, JSEI, UCLA Sch. of Med., Ctr. for Health Sciences, Los Angeles 90024. (213) 825-4617.
- April 30-May 7—**Management of the Surgical Patient.** STAN at Mauna Kea Beach Hotel, Kamuela. One week. 25 hrs. \$365.
- May 1-4—**Preparation for Surgery: Medical Evaluation of the Preoperative Patient.** UCD at Doubletree Inn, Monterey. Sunday-Wednesday.
- May 5-7—**Postgraduate Course in General Surgery.** UCSF at Fairmont, San Francisco. Thursday-Saturday.
- May 6-9—**Intensive Course in Refractive Keratoplasty: Barraquer Technique.** Jules Stein Eye Institute, Los Angeles. Friday-Monday. 32 hrs. \$1,750. Contact: Lu Hendricks, JSEI, UCLA School of Medicine, Los Angeles 90024. (213) 825-4617.
- May 14—**The First 100 Valves EMC Experience.** Heart Institute of the Desert, Eisenhower Medical Center at Eisenhower Medical Center, Rancho Mirage. Saturday. 1½ hrs. Contact: Heart Institute of the Desert, 39000 Bob Hope Dr., Rancho Mirage. (619) 568-2900.
- May 21—**Clinical Update Program in Ophthalmic Genetics.** Jules Stein Eye Institute, Los Angeles. Saturday. 8 hrs. \$35. Contact: Lu Hendricks, JSEI, UCLA School of Medicine, Center for Health Sciences, Los Angeles 90024. (213) 825-4617.
- May 26-27—**Neurosurgery Postgraduate Course.** UCSF at Hilton, San Francisco. Thursday-Friday.
- June 2-4—**OTO 83.** Project HEAR at Hyatt Regency, San Francisco. Thursday-Saturday. 24 hrs. Contact: Project HEAR, 1801 Page Mill Rd., Palo Alto 94304. (415) 494-2000.
- June 3-4—**Ophthalmology Update on Basic Sciences for the Clinician.** UCD, PMC, UCSF, STAN at San Franciscan Hotel, San Francisco. Friday-Saturday. Contact: Update, 3910 Sand Hill Rd., Woodside 94062. (415) 563-4321, ext. 2763.
- June 11—**Techniques of Laser Treatment for Glaucoma.** Jules Stein Eye Institute, Los Angeles. Saturday. 8 hrs. \$400. Contact: Lu Hendricks, JSEI, UCLA Sch. of Med., Ctr. for Health Sciences, Los Angeles 90024. (213) 825-4617.
- June 11-17—**Orthopaedic Review Course.** UCSF at Golden Gateway Holiday Inn, San Francisco. Saturday-Tuesday.
- June 16-18—**Cosmetic Blepharoplasty Workshop.** Jules Stein Eye Institute, Los Angeles. Thursday-Saturday. Contact: Lu Hendricks, JSEI, UCLA Sch. of Med., Ctr. for Health Sciences, Los Angeles 90024. (213) 825-4617.
- June 22-24—**10th Annual Conference: Cochlear Implants.** UCSF. Wednesday-Friday.

OF INTEREST TO ALL PHYSICIANS

- February 20-25—**Winter Sports Injuries—An In-Depth Course.** UCD at Hyatt, Lake Tahoe. Sunday-Friday. 24 hrs.
- February 21-25—**Basic Science for Clinicians.** STAN. Monday-Friday. 25 hrs. \$365.
- February 23-March 2—**Lifestyle Medicine Convention.** LLU. One week. 27 hrs.
- February 26-March 5—**Management of Pain.** University of Washington School of Medicine at Kauai Surf, Kauai. One

week. Contact: University of Washington School of Medicine, Division of CME, SC-50, Seattle, WA 98195. (206) 543-1050.

- March 3-6—**Critical Care Medicine—21st Annual Symposium.** USC at MGM Grand, Las Vegas. Thursday-Sunday. 28 hrs.
- March 5-6; 19-20—**San Francisco Academy of Hypnosis—Annual Workshop.** Letterman Army Medical Center, San Francisco. Two weekends. 28 hrs. \$275. Contact: Jan Brooks, SFAH, 2820 15th Ave., San Francisco 94114.
- March 5-12—**Future Directions and Update on Family Practice.** Univ. of Washington School of Medicine at Sheraton Royal Waikiloa, Kona. One week. Contact: U/W Sch. of Med., Div. of CME, SC-50, Seattle 98195. (206) 543-1050.
- March 9-11—**33rd Annual Course for Physicians in Family Practice.** Mt. Zion Hospital and Medical Center, San Francisco. Wednesday-Friday. Contact: Nancy Drungilas, Office of Cont. Ed., Mt. Zion Hosp., P.O. Box 7921, San Francisco 94120. (415) 567-6600, ext. 2404.
- March 9-11—**American Society for Clinical Pharmacology and Therapeutics.** Town and Country Hotel, San Diego. Wednesday-Friday. Contact: ASCPT, 1718 Gallagher Rd., Norristown, PA 19401.
- March 10-13—**Clinical Management.** STAN at The Lodge, Pebble Beach. Thursday-Sunday. 12 hrs. \$250.
- March 11-16—**California Medical Association—112th Annual Session.** Bonaventure Hotel, Los Angeles. Friday-Wednesday. Contact: Joan Kammerer, CMA.
- March 12—**Total Parenteral Nutrition.** UCLA. Saturday.
- March 14-18—**Sports Medicine.** University of Hawaii at Princess Kaiulani Hotel, Waikiki, Honolulu. Monday-Friday. 18 hrs. \$250. Contact: Ms Joy Lewis, Box CEW-CCECS, 2530 Dole St., Honolulu 96822. (808) 948-8244.
- March 24—**Symposium on Sexually Transmitted Diseases.** California VD Controllers' Association, Southern California Public Health Association, and Riverside County Department of Health at Raincross Square, Riverside. Thursday. 4 hrs. \$25. Contact: Venereal Disease Control, Riverside Dept. of Health, P.O. Box 1370, Riverside 92502. (714) 787-2042.
- March 26—**Alcoholism and Its Treatment: 1983.** UCD at Sacramento Inn, Sacramento. Saturday. 7 hrs.
- April 8—**Common Problems in an Aging Population.** LLU at Casa Royale Motor Inn, Bakersfield. Friday. 6 hrs.
- April 13—**Antibiotic Update—1983.** LLU. Wednesday. 4 hrs.
- April 14-16—**Postgraduate Institute.** CMA at Ahwahnee Hotel, Yosemite. Thursday-Saturday. Contact: Charlotte Newhart, CMA.
- April 20-24—**Mountain Medicine.** UCD at Stanford Sierra Lodge, Fallen Leaf Lake. Wednesday-Sunday. 29 hrs.
- April 30-May 1—**11th Annual Family Practice Symposium.** Southern California Permanente Medical Group at Hilton, Pasadena. Saturday-Sunday. 12 hrs. \$150. Contact: Office of Education and Research, SCPMG, 4747 Sunset Blvd., Los Angeles 90027. (213) 667-4241.
- June 8-10—**8th Annual Conference on Clinical Application of Hyperbaric Oxygen.** Memorial Hospital Medical Center, Long Beach. Wednesday-Friday. 18 hrs. Contact: Michael B. Strauss, MD, Baromedical Dept., Memorial Hospital Medical Center, 2801 Atlantic Ave., Long Beach 90801. (213) 595-3613.
- June 13-18—**UCI Family Practice Refresher Course.** UCI at Marriott, Anaheim. Monday-Saturday. 50-56 hrs.
- June 23-27—**Golden State Medical Association—Annual Convention in San Diego.** Thursday-Monday. Contact: GSMA, P.O. Box 2151-Station A, Berkeley 94702. (415) 839-3466.

THEO-DUR®

(anhydrous theophylline)
Sustained Action Tablets

**Today's most
widely prescribed
bronchodilator.**

Description: THEO-DUR Sustained Action Tablets contain anhydrous theophylline, with no color additives.

Pharmacologic Actions: The pharmacologic actions of theophylline are as a bronchodilator, pulmonary vasodilator and smooth muscle relaxant since the drug directly relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels. Theophylline also possesses other actions typical of the xanthine derivatives: coronary vasodilator, diuretic, cardiac stimulant, cerebral stimulant and skeletal muscle stimulant. The actions of theophylline may be mediated through inhibition of phosphodiesterase and a resultant increase in intracellular cyclic AMP which could mediate smooth muscle relaxation.

Indications and Usage: Symptomatic relief and/or prevention of asthma and reversible bronchospasm associated with chronic bronchitis and emphysema.

Contraindications: THEO-DUR is contraindicated in individuals who have shown hypersensitivity to any of its components or xanthine derivatives.

Warnings: Excessive theophylline doses may be associated with toxicity; serum theophylline levels should be monitored to assure maximum benefit with minimum risk. Incidence of toxicity increases at serum levels greater than 20 mcg/ml. High blood levels of theophylline resulting from conventional doses are correlated with clinical manifestation of toxicity in: patients with lowered body plasma clearances, patients with liver dysfunction or chronic obstructive lung disease, and patients who are older than 55 years of age, particularly males. There are often no early signs of less serious theophylline toxicity such as nausea and restlessness, which may appear in up to 50% of patients prior to onset of convulsions. Ventricular arrhythmias or seizures may be the first signs of toxicity. Many patients who have higher theophylline serum levels exhibit a tachycardia. Theophylline products may worsen pre-existing arrhythmias.

Usage in Pregnancy: Safe use in pregnancy has not been established relative to possible adverse effects on fetal development, but neither have adverse effects on fetal development been established. This is, unfortunately, true for most anti-asthmatic medications. Therefore, use of theophylline in pregnant women should be balanced against the risk of uncontrolled asthma.

Precautions: THEO-DUR TABLETS SHOULD NOT BE CHEWED OR CRUSHED. Theophyllines should not be administered concurrently with other xanthine medications. It should be used with caution in patients with severe cardiac disease, severe hypoxemia, hypertension, hyperthyroidism, acute myocardial injury, cor pulmonale, congestive heart failure, liver disease, and in the elderly, particularly males, and in neonates. Great caution should be used in giving theophylline to patients in congestive heart failure since these patients show markedly prolonged theophylline blood level curves. Use theophylline cautiously in patients with history of peptic ulcer. Theophylline may occasionally act as a local irritant to G.I. tract, although gastrointestinal symptoms are more commonly central and associated with high serum concentrations above 20 mcg/ml.

Adverse Reactions: The most consistent adverse reactions are usually due to overdose and are:

Gastrointestinal: Nausea, vomiting, epigastric pain, hematemesis, diarrhea.

Central Nervous System: Headaches, irritability, restlessness, insomnia, reflex hyperexcitability, muscle twitching, clonic and tonic generalized convulsions.

Cardiovascular: Palpitation, tachycardia, extrasystoles, flushing, hypotension, circulatory failure, life threatening ventricular arrhythmias.

Respiratory: Tachypnea.

Renal: Albuminuria, increased excretion of renal tubular cells and red blood cells, potentiation of diuresis.

Others: Hyperglycemia and inappropriate ADH syndrome.

How Supplied: THEO-DUR 100 mg, 200 mg and 300 mg Sustained Action Tablets are available in bottles of 100, 500, 1000, and 5000, and in unit dose packages of 100.

Caution: FEDERAL LAW PROHIBITS DISPENSING WITHOUT A PRESCRIPTION.

For full prescribing information, see package insert.

0881

KEY
PHARMACEUTICALS, INC.
Miami, Florida 33169 (USA)

**World leader in
drug delivery systems.**

TD-1170

(Continued from Page 199)

July 5-7—**Family Practice Board Review Course.** UCSF. Tuesday-Thursday.

IDAHO

February 19-26—**Updates in Acute Medicine: An Epic Medical Expedition—Alpine Skiing Conference** (Sponsors: American Institute of Primary Care Medicine and the University of Arizona College of Medicine). Sun Valley. Saturday-Saturday. 24 credit hrs. Contact: Richard Paris, MD, PO Box 209, Sun Valley, ID 83353.

March 19-26—**Updates in Trauma: An Epic Medical Expedition—Alpine Skiing Conference** (Sponsors: American Institute of Primary Care Medicine and the University of Arizona College of Medicine). Sun Valley. Saturday-Saturday. 24 credit hrs. Contact: Richard Paris, MD, PO Box 209, Sun Valley, ID 83353.

August 15-19—**Pediatric Immunology and Infectious Disease** (Sponsor: University of Utah). Monday-Friday. Sun Valley. 25 hrs. Fee to be announced. Contact: John Matsen, MD, (801) 581-5968.

See also Washington Listings: February 19-26.

MONTANA

March 26-April 2—**Updates in Pediatrics: An Epic Medical Expedition—Ski Touring Conference** (Sponsors: American Institute of Primary Care Medicine and the University of Arizona College of Medicine). Big Sky. Saturday-Saturday. Lone Mountain Ranch. 24 credit hrs. Contact: Richard Paris, MD, PO Box 209, Sun Valley, ID 83353.

NEW MEXICO

All courses listed below have been certified by CME accredited institutions as meeting the criteria for Category 1 of the Physician's Recognition Award of the American Medical Association. The Continuing Medical Education Committee of the New Mexico Medical Society has certified all courses listed below as meeting the criteria for Category IV under the New Mexico Board of Medical Examiners Continuing Medical Education regulations.

Information, requests for accreditation and items to be listed should be sent to the chairman of the CME Committee, New Mexico Medical Society, 303 San Mateo NE, Suite 204, Albuquerque, NM 87108 at least two months in advance. For information on CME accreditation or on the CME requirements of the New Mexico Board of Medical Examiners, please write to the above address or call (505) 266-7868.

NOTE: Course information in the following listing is subject to change on occasion. Check with the sponsoring institution for current details.

February 27-March 3—**New Mexico Metabolism Symposium.** Taos. Sunday-Thursday. Tennis Ranch of Taos. 15 credit hours. Contact: Martin Conway, MD, Lovelace Medical Center, 5400 Gibson Blvd. SE, Albuquerque, NM 87108. (505) 842-7000.

February 28-March 4—**Purgatory Ski Symposium.** Durango, Colorado. Monday-Friday. Tamaron Lodge. 20 credit hours,

(Continued on Page 292)

THE WESTERN JOURNAL OF MEDICINE

INFORMATION FOR AUTHORS

Submitting Manuscripts

Manuscripts for consideration should be sent to the editor, Malcolm S. M. Watts, MD, 731 Market Street, San Francisco, California 94103. The transmittal letter should designate one person as correspondent and include complete address, with ZIP code and telephone number.

In view of *The Copyright Revision Act of 1976*, transmittal letters should contain the following language: "In consideration for reviewing and editing my submission, the author(s) undersigned hereby transfers, assigns or otherwise conveys all copyright ownership to THE WESTERN JOURNAL OF MEDICINE in the event that such work is published by the journal." This statement should be signed by *all* the authors.

Authors are urged to seek clarity and succinctness in all manuscripts regardless of subject matter or format and to give close attention to syntax, grammar and spelling.

Clinical Investigation Section

Articles that authors wish to have considered for the Clinical Investigation section should be so designated in the transmittal letter. The type of articles appropriate for this section are those that describe experimental work in humans that extensively and prospectively examines scientific hypotheses relating to disease. An article describing a single case report will not normally be considered appropriate for this section.

Preparing Manuscripts

The original manuscript and *two* copies should be submitted on heavy bond paper (8½ by 11 inches, *not* erasable), typed double-spaced throughout (including legends, tables and references) on one side of the paper, with 1½-inch margins. Ordinarily, articles should not exceed 3,000 words (less than 15 text pages, typed double-spaced). Under exceptional circumstances only will articles longer than 4,000 words be published. Pages should be numbered consecutively, beginning with the title page.

Style

Abbreviations. Use of abbreviations should be minimized. If they are necessary, abbreviations should be spelled out at first mention, with the abbreviation itself immediately following in parentheses.

Weights and measures. All measurements should be given in metric units. English equivalents should be given parenthetically if the measurements were originally done in English units.

Temperatures. Temperature readings should be given first in Celsius, followed by the Fahrenheit equivalent in parentheses.

Drug names. If the trade name of a drug is used, the generic name should be given first, followed by the trade name in parentheses. Trade names are capitalized, generic names are not.

Title Page

Titles are best when brief and concise. The title page should include the full name of the author(s), with degrees, academic or professional titles, complete addresses and any institutional or other affiliations. The complete name and address of the person who will handle reprint requests also should appear on this page.

Abstract

The abstract (approximately 150 words) should be a short summary, saying in brief what is said at length in the body of the article—rather than such and such "is discussed," "is presented" or "was investigated."

Tables and Figures

Tables

Each table should be typed on a separate sheet of paper, be numbered consecutively in Arabic numerals, have a brief descriptive title and have its position indicated in the text.

Illustrations (Figures)

Three sets of clear, unmounted black and white glossy prints of figures should be submitted (preferably 5 by 7 inches, but no larger than 8½ by 11 inches). For line drawings, original artwork or glossy prints are acceptable. Illustrations should be numbered consecutively in Arabic numerals and their position indicated in the text. Figure number, first author's name and top of the photo should be shown on the reverse side of each illustration. Recognizable photographs of patients are to be masked and written permission for publication obtained from the patients.

Legends

All legends for figures should be typed together on a separate sheet of paper. Magnification and stain for photomicrographs should be indicated in parentheses.

Permission for Reproduction

If an illustration or table has been used previously in another publication, written permission for its use must be obtained from the publisher, and should accompany the manuscript. The source should be acknowledged in the legend if it can be done

briefly by citation of a reference number. Otherwise, acknowledgment is made at the end of the figure legend or at the bottom of the table.

References

References should be limited to those cited in the text. They must be typed double-spaced and numbered consecutively as they appear in the manuscript. (See examples below for style.) Abbreviations of journal titles should conform to those used in *Index Medicus*.

Journal Articles

Note handling of multiple authorship. If more than three authors are listed as contributors, use "et al" to designate those names after the first three. Also note capitalization, punctuation, mention of inclusive page numbers, and month and year of publication. Separate the subtitle from the title by either a dash or a colon. Use colon *only* if it appears in the original citation.

1. Jones JS, Andersen HW, Johnson DW, et al: The athletic heart revisited—Sudden death of a 28-year-old athlete. *JAMA* 1978 Apr 26; 292:444-456

2. Graybill JR, Alford RH, Smith RG, et al: Cell-mediated immunity in cryptococcosis: A brief review. *Cell Immunol* 1978 Sep; 7:76-79

Books

Note handling of "edition," "editor(s)," and "volume," as well as appropriate sequence of reference information and capitalization of chapters and titles.

3. Berne EJ, Smith TL: Role playing in therapy, chap 2, *Principles of Group Therapy*. New York, Oxford University Press, 1966, pp 35-51 (*author of chapter same as author of book*)

4. Munsung JM: The role of drugs, chap 2, *In* Brest AN, Mayer JH (Eds): *Hypertension—Vol 2, Therapy*, 2nd Ed. Springfield, Ill, Charles C Thomas, 1961, pp 456-479 (*author of chapter different from authors of book*)

Pamphlets, Monographs or Books With No Given Author

5. AMA Department of Drugs: *AMA Drug Evaluation*, 3rd Ed. Littleton, Mass, Publishing Sciences Group, 1977 (*corporate author*)

6. *Compilation of Standard Definitions*, 3rd Ed. Philadelphia, American Society for Testing and Materials, 1976 (*no given author; give name and place of publisher*)

Articles in Press or Accepted for Publication

Any article accepted for publication should include the name of the journal (appropriately abbreviated) in which it will appear, and the phrase "in press" or "accepted for publication" in place of the date of publication.

Personal Communications and Unpublished Data

This information should *not* be included in the reference list but should be given in parentheses in the body of the text. Date of communication, whether it was personal or written, and the person's name, highest academic degree and professional affiliation should be provided.

Acknowledgments

It is the policy of the *WJM* not to print acknowledgments, the feeling being that if a person has contributed enough to a paper to be mentioned, he or she should be included among the authors, or the contribution should be mentioned in the body of the paper or in a footnote.

Correspondence

Brief manuscripts commenting on articles that have appeared in the journal, containing information of interest to physicians or discussing issues of the day will be considered for publication. Very short reports of cases, clinical experience, clinical studies, adverse effects and the like also will be considered. Items for the Correspondence section should not exceed 600 words and should have no more than five bibliographic references and one figure or table.

Author Responsibility

Authors are responsible for all statements made in articles. Manuscripts are considered for publication with the explicit understanding that they are original, have not been published previously and are not simultaneously under consideration by any other publication.

All accepted manuscripts are subject to copy editing, and authors are sent edited galleys for approval. No changes will be made after the final, edited version has been approved by the author.

Reprints

If reprints are desired, they must be paid for by the author. A reprint order form with schedule of prices is sent to the author when the article is published. Authors are responsible for handling requests for reprints of their articles.

(Continued from Page 202)

also AAFP. Contact: Gwenn Robinson, MD, 303 San Mateo NE, Suite 204, Albuquerque, NM 87108. (505) 266-7868.

May 4-6—**New Mexico Medical Society Annual Meeting.** Albuquerque. Wednesday-Friday. Four Seasons Motor Lodge. 12 credit hours, NM Category IV and AMA Category I. Contact: New Mexico Medical Society, 303 San Mateo NE, Suite 204, Albuquerque, NM 87108. (505) 266-7868.

OREGON

The following list of continuing medical education offerings in the state of Oregon is compiled by the Oregon Medical Association's Council on Medical Education. If you wish to submit information regarding future postgraduate courses, please submit the information to Veronica Story, Secretary to the Council on Medical Education, 5210 SW Corbett Ave., Portland, OR 97201, or phone (503) 226-1555.

MEDICAL GRAND ROUNDS

Douglas Community Hospital, 738 West Harvard Avenue, Roseburg 97470:

Every Monday 12:30 p.m. Contact: Robert A. Driver, MD, Douglas Community Hospital, 738 West Harvard Avenue, Roseburg, OR 97470. (503) 673-6641.

Emanuel Hospital, 2801 N. Gantenbein Street, Portland 97227:

Every Friday, 8:00 a.m. to 9:00 a.m. **Medical Grand Rounds.** Contact: Philipa McClure, Emanuel Hospital, 2801 N. Gantenbein St., Portland, OR 97227. (505) 280-3200.

Good Samaritan Hospital and Medical Center, 1015 NW 22nd Avenue, Portland 97210:

Every Wednesday, 8:00 a.m. to 9:00 a.m. **Medicine Grand Rounds.** Contact: Chris Cobb, Good Samaritan Hospital and Medical Center, 1015 NW 22nd Avenue, Portland, OR 97201. (503) 229-7111.

Providence Medical Center, 700 NE 47th Ave., Portland 97213:

Every Wednesday, 8:00 a.m. **Medical Grand Rounds.** Contact: Martha Regan, MD, Providence Medical Center, 700 NE 47th Ave., Portland, OR 97213. (503) 234-8211.

Sacred Heart General Hospital, 1200 Alder Street, Eugene, OR 97440:

Every Tuesday, 8:00-9:00 a.m. **Medical Grand Rounds.** Hospital Auditorium. Contact: Medical Education Committee, P.O. Box 10905, Eugene, OR 97440.

Salem Hospital, 665 Winter Street SE, Salem 97301:

First and third Thursday of each month 7:15 a.m. to 8:15 a.m. **Medical Live Audit Conference.** Memorial Auditorium. Contact: Diane Eyerly, Salem Hospital, 665 Winter St. SE, Salem, OR 97301. (503) 370-5339.

Every Friday, 7:30 a.m. to 8:30 a.m. **Friday Grand Rounds.** Memorial Auditorium. Contact: Diane Eyerly, Salem Hospital, 665 Winter St. SE, Salem, OR 97301. (503) 370-5339.

St. Vincent Hospital & Medical Center, 9205 SW Barnes Rd., Portland 97225:

First, third, fourth and fifth Wednesday of each month, 8:00 a.m. to 9:00 a.m. **Medical Grand Rounds.** Souther Auditorium. Contact: Bonnie Conger, Secretary to Dr. Kenneth Melvin, St. Vincent Hospital & Medical Center, 9205 SW Barnes Rd., Portland 97225. (503) 297-4411, Ext. 2230.

Oregon Health Sciences University, Department of Psychiatry, Portland 97201:

Every Wednesday, 4:00 p.m. to 5:00 p.m.—**Department of Psychiatry Grand Round Presentations.** Room 8B-60, University Hospital South, Oregon Health Sciences University. Contact: Dept. of Psychiatry, Oregon Health Sciences University, Portland, OR 97201. (503) 225-8144.

Oregon Health Sciences University, Department of Medicine, Portland 97201:

Every Tuesday, 8:00 a.m. to 9:00 a.m.—**Department of Medicine Grand Rounds.** Library Auditorium, Oregon Health Sciences University. Contact: Dept. of Medicine, Oregon Health Sciences University, Portland, OR 97201. (503) 225-8607.

FAMILY PRACTICE GRAND ROUNDS

Every Wednesday, 11:00 a.m. to 12:00 Noon. **Family Practice Grand Rounds.** Family Practice Center, Oregon Health Sciences University, Portland. Contact: William A. Fisher, MD, Oregon Health Sciences University, Department of Family Practice, Portland, OR 97201. (503) 225-7590.

* * * *

FAMILY PRACTICE

February 14-18—**Annual Family Practice Review.** Portland. Monday-Friday. Red Lion Motor Inn at Lloyd Center. For information contact: OHSU-CME.

PATHOLOGY

March 10-11—**Workshop in Dermatopathology.** Portland. Thursday-Friday. Oregon Medical Association, 5210 SW Corbett. For information contact: OHSU-CME.

INTEREST TO ALL PHYSICIANS

March 4-5—**Complex and Controversial Issues in Multiple System Trauma.** Portland. Friday-Saturday. Red Lion Inn Downtown. For information contact: OHSU-CME.

March 11-12—**1983 Mid-Willamette Valley Cancer Conference on Lung Cancer.** Gleneden Beach. Friday-Saturday. Salishan Lodge. For information contact: Beverly Kay, Executive Secretary, Salem Hospital, P.O. Box 14001, Salem, OR 97309. (503) 370-5339.

April 8-10—**Spring at Mt. Bachelor: Rheumatology Update 1983.** Bend. Friday-Sunday. Inn of the Seventh Mountain. For information contact: OHSU-CME.

April 13-15—**Sommer Memorial Lectures/Alumni Association Scientific Sessions.** Portland. Wednesday-Friday. Oregon Health Sciences University Campus. For information contact: OHSU-CME.

May 20-21—**Orthopedics for the Primary Care Physician.** Portland. Friday-Saturday. Red Lion Motor Inn-Lincoln St. For information contact: OHSU-CME.

June 16-18—**Current Concepts in Cardiology.** Ashland. Thursday-Saturday. Ashland Hills Inn. For information contact: OHSC-CME.

CONTACT INFORMATION

OHSU-CME—Contact: Division of Continuing Medical Education, Oregon Health Sciences University, Portland, OR 97201. (503) 225-8700.

UTAH

This listing of continuing medical education courses in Utah is compiled and edited by the Academy for Continuing Medical Education, a foundation of the Utah State Medical Association. All courses listed have been certified by CME accredited institutions as meeting the criteria for Category 1 of the Physician's Recognition Award of the American Medical Association. They also must meet the definition of Utah Approved CME Credit for the purpose of medical license reregistration in Utah. Accredited institutions wish-

(Continued on Page 303)

Brief Summary of prescribing information

RU-TUSS®

TABLETS

INDICATIONS AND USAGE: Ru-Tuss Tablets provide relief of the symptoms resulting from irritation of sinus, nasal and upper respiratory tract tissues.

CONTRAINDICATIONS: Hypersensitivity to antihistamines or sympathomimetics. Ru-Tuss Tablets are contraindicated in children under 12 years of age and in patients with glaucoma, bronchial asthma and women who are pregnant. Concomitant use of MAO inhibitors is contraindicated.

WARNINGS: Ru-Tuss Tablets may cause drowsiness. Patients should be warned of possible additive effects caused by taking antihistamines with alcohol, hypnotics, sedatives or tranquilizers.

PRECAUTIONS: Ru-Tuss Tablets contain belladonna alkaloids, and must be administered with care to those patients with urinary bladder neck obstruction. Caution should be exercised when Ru-Tuss Tablets are given to patients with hypertension, cardiac or peripheral vascular disease or hyperthyroidism. Patients should avoid driving a motor vehicle or operating dangerous machinery (See WARNINGS:).

OVERDOSAGE: Since the action of sustained release products may continue for as long as 12 hours, treatment of overdoses directed at reversing the effects of the drug and supporting the patient should be maintained for at least that length of time. Saline cathartics are useful for hastening evacuation of unreleased medication. In children and infants, antihistamine overdosage may produce convulsions and death.

ADVERSE REACTIONS: Hypersensitivity reactions such as rash, urticaria, leukopenia agranulocytosis, and thrombocytopenia may occur. Other adverse reactions to Ru-Tuss Tablets may be drowsiness, lassitude, giddiness, dryness of the mucous membranes, tightness of the chest, thickening of bronchial secretions, urinary frequency and dysuria, palpitation, tachycardia, hypotension/hypertension, faintness, dizziness, tinnitus, headache, incoordination, visual disturbances, mydriasis, xerostomia, blurred vision, anorexia, nausea, vomiting, diarrhea, constipation, epigastric distress, hyperirritability, nervousness, dizziness and insomnia. Large overdoses may cause tachypnea, delirium, fever, stupor, coma and respiratory failure.

DOSAGE AND ADMINISTRATION: Adults and children over 12 years of age, one tablet morning and evening. Not recommended for children under 12 years of age. Tablets are to be swallowed whole.

Federal law prohibits dispensing without prescription.



Boots Pharmaceuticals, Inc.
Shreveport, LA 71106
Pioneers in medicine for the family

(Continued from Page 292)

ing to list AMA Category 1/Utah Approved CME courses here should send information at least two months in advance to the Academy for Continuing Medical Education, 540 East Fifth South, Salt Lake City, Utah 84102; or phone (801) 355-5290. For information on CME accreditation or on the CME requirements of the Utah Physicians' Licensing Board, please write the Academy at the above address.

NOTE: Course information in the following listing is subject to change on occasion. Check with the sponsoring institution or the Academy for current details.

PEDIATRIC GRAND ROUNDS

Primary Children's Medical Center, 320 12th Ave., Salt Lake City 84103:

First and Third Thursdays—8:00 a.m. Contact: Cathy Van Komen, PCMC, 320 12th Ave., Salt Lake City, UT 84103. (801) 363-1221.

MONTHLY PSYCHOTHERAPY CLINICAL SEMINAR

Holy Cross Hospital, 1045 East First South, Salt Lake City 84102.

First Monday—7-9 a.m. Contact: Jack Tedrow, MD, (801) 363-2024.

FAMILY PRACTICE CLINICAL CONFERENCE

Holy Cross Hospital, 1045 East First South, Salt Lake City 84102.

Every Friday—7:30-8:30 a.m. Contact: Thomas Schwenk, MD, (801) 350-4111.

CITYWIDE OB/GYN CLINICAL CONFERENCE

Holy Cross Hospital, 1045 East First South, Salt Lake City 84102.

Second Saturday—8-9 a.m. Contact: Howard Berk, MD, (801) 364-4438.

SPONSORS OF COURSES—ABBREVIATIONS

- AF: Arthritis Foundation, 1174 East 2700 South, Salt Lake City 84117. (801) 466-9389.
- CH: Castlevue Hospital (formerly Carbon Hospital), RFD 2, Box 46, Price, UT 84501. (801) 637-4800.
- CWH: Cottonwood Hospital, 5770 South 300 East, Salt Lake City 84101. (801) 262-3461.
- FHP: Family Health Program/Utah, 323 South Sixth East, Salt Lake City 84102. (801) 335-1234. Contact: Kay Schultz for course information.
- HAFB: Hill Air Force Hospital, Hill Air Force Base 84406. (801) 777-1262.
- HCH: Holy Cross Hospital, 1045 East First South, Salt Lake City 84102. (801) 350-4744.
- LDSh: Latter-Day Saints Hospital, 325 8th Avenue, Salt Lake City 84143. (801) 350-1100.
- MDH: McKay-Dee Hospital Center, 3939 Harrison Blvd., Ogden 84409. (801) 399-4141.
- OEH: Rocky Mountain Center for Occupational and Environmental Health, 50 North Medical Drive, Salt Lake City 84132. (801) 581-8719.
- OSS: Ogden Surgical Society, PO Box 9311, Ogden 84409.
- PCMC: Primary Children's Medical Center, 320 12th Ave., Salt Lake City 84103. (801) 363-1221.
- SHCC: Shriners Hospital for Crippled Children, Intermountain Unit, Fairfax Ave. at Virginia St., Salt Lake City 84103. (801) 532-5307.
- SLSC: Salt Lake Surgical Center, 617 East 3900 South, Salt Lake City 84117. (801) 261-3141.
- UAFFP: Utah Academy of Family Physicians, 1146 Westminster Ave., Salt Lake City 84105. (801) 466-9478.
- UUMC: University of Utah Medical Center, 50 North Medical Drive, Salt Lake City 84132. (801) 581-2258.
- USMA: Utah State Medical Association, 540 East Fifth South, Salt Lake City 84102. (801) 355-7477.
- UVH: Utah Valley Hospital, 1034 North Fifth West, Provo 84601. (801) 373-7850.
- VAMC: Veterans Administration Medical Center, 500 Foothill Drive, Salt Lake City 84148. (801) 582-1565.

OB/GYN PATHOLOGY CONFERENCE

Holy Cross Hospital, 1045 East First South, Salt Lake City 84102.

Fourth Monday—8-9 a.m. Contact: Howard Berk, MD, (801) 364-4438.

MONTHLY OPHTHALMOLOGY FLUORESCIN ANGIOGRAPHY CONFERENCE

Holy Cross Hospital, 1045 East First South, Salt Lake City 84102.

Fourth Monday—7:30-8:30 a.m. Contact: Roy Goodart, MD, (801) 532-7406 or F. T. Reikhof, MD, (801) 532-7406.

INTERDEPARTMENTAL GRAND ROUNDS

Utah Valley Hospital, Provo, 1034 North Fifth West, Provo 84601.

Contact: Gary Watts, MD, UVH, 1034 North Fifth West, Provo, UT 84601. (801) 373-7850 (Ext 2143).

* * * *

February 18-22—**28th Annual Postgraduate Course in Anesthesiology** (Sponsor: University of Utah). Salt Lake City. Friday-Tuesday. Hilton Hotel. 17 hrs. Fee to be announced. Contact: Ted Stanley, MD (801) 581-7647.

February 19-22—**24th Annual Ob/GYN Postgrad Course** (Sponsor: University of Utah). Park City. Saturday-Tuesday. 15 hrs. \$275. Contact: David Engleberg (801) 581-7647.

February 23-26—**Perinatal Update** (Sponsor: University of Utah). Park City. Wednesday-Saturday. 15 hrs. \$275. Contact: David Engleberg (801) 581-7647.

February 25—**Special Problems in Stroke Recovery** (Sponsor: McKay-Dee Hospital Center). Ogden. Thursday. 1 hr. No fee. Contact: (801) 627-3202.

February 26-27—**Head, Neck/Spine CT** (Sponsor: University of Utah). Salt Lake City. Saturday-Sunday. Little America Hotel. 11 hrs. Fee to be announced. Contact: Robert Anderson, MD (801) 581-8188.

March 2-4—**Intermountain Pediatric Society/Common Problems in Pediatrics** (Sponsor: University of Utah). Salt Lake City. Wednesday-Friday. 15 hrs. \$200. Contact: Richard O'Brien, MD (801) 363-1221/#250.

March 4—**Blood and Marrow Neutrophil Kinetics During Group B Streptococcal Sepsis/Interdepartmental Research Seminar** (Sponsor: University of Utah). Salt Lake City. Friday. School of Medicine. 1 hr. No fee. Contact: Rosalie Lammle (801) 581-8664.

March 5-6—**Digital Angiography/Interventional Medicine** (Sponsor: University of Utah). Salt Lake City. Saturday-Sunday. Little America Hotel. 12.5 hrs. Fee to be announced. Contact: Franklin Miller, MD (801) 581-8188.

March 7-11—**Medical and Surgical Advances in Gastroenterology** (Sponsor: University of Utah). Snowbird. Monday-Friday. 22.5 hrs. \$275. Contact: Jennifer Fossum (801) 581-3581.

March 10-11—**Rocky Mountain Infection Control Association/Infection Control Update** (Sponsor: University of Utah). Salt Lake City. Thursday-Friday. Little America Hotel. 12 hrs. \$85-\$100. Contact: Sego Matsumiya, RN (801) 582-1565.

March 11—**Forensic Pathology Seminar** (Sponsor: University of Utah). Salt Lake City. Friday. Skaggs Hall, University Medical Center. 7 hrs. \$85. Contact: Wallace Graham, MD (801) 533-5848.

March 14-19—**Basic Science Update/Practicing MD's: Impact of Modern Biology on Medical Practice** (Sponsor: Univer-

BRIEF SUMMARY PROCARDIA® CAPSULES

For Oral Use

(nifedipine)
INDICATIONS AND USAGE: 1. **Vasospastic Angina:** PROCARDIA (nifedipine) is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. PROCARDIA may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers.

2. **Chronic Stable Angina (Classical Effort-Associated Angina):** PROCARDIA is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents.

In chronic stable angina (effort-associated angina) PROCARDIA has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in those patients are incomplete.

Controlled studies in small numbers of patients suggest concomitant use of PROCARDIA and beta blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (See Warnings.)

CONTRAINDICATIONS: Known hypersensitivity reaction to PROCARDIA.

WARNINGS: **Excessive Hypotension:** Although in most patients, the hypotensive effect of PROCARDIA is modest and well tolerated, occasional patients have had excessive and poorly tolerated hypotension. These responses have usually occurred during initial titration or at the time of subsequent upward dosage adjustment, and may be more likely in patients on concomitant beta blockers.

Severe hypotension and/or increased fluid volume requirements have been reported in patients receiving PROCARDIA together with a beta blocking agent who underwent coronary artery bypass surgery using high dose fentanyl anesthesia. The interaction with high dose fentanyl appears to be due to the combination of PROCARDIA and a beta blocker, but the possibility that it may occur with PROCARDIA alone, with low doses of fentanyl, in other surgical procedures, or with other narcotic analgesics cannot be ruled out.

Increased Angina: Occasional patients have developed well documented increased frequency, duration or severity of angina on starting PROCARDIA or at the time of dosage increases. The mechanism of this response is not established but could result from decreased coronary perfusion associated with decreased diastolic pressure with increased heart rate, or from increased demand resulting from increased heart rate alone.

Beta Blocker Withdrawal: Patients recently withdrawn from beta blockers may develop a withdrawal syndrome with increased angina, probably related to increased sensitivity to catecholamines. Initiation of PROCARDIA treatment will not prevent this occurrence and might be expected to exacerbate it by provoking reflex catecholamine release. There have been occasional reports of increased angina in a setting of beta blocker withdrawal and PROCARDIA initiation. It is important to taper beta blockers if possible, rather than stopping them abruptly before beginning PROCARDIA.

Congestive Heart Failure: Rarely, patients, usually receiving a beta blocker, have developed heart failure after beginning PROCARDIA. Patients with tight aortic stenosis may be at greater risk for such an event.

PRECAUTIONS: **General:** **Hypotension:** Because PROCARDIA decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of PROCARDIA is suggested. Close observation is especially recommended for patients already taking medications that are known to lower blood pressure. (See Warnings.)

Peripheral edema: Mild to moderate peripheral edema, typically associated with arterial vasodilation and not due to left ventricular dysfunction, occurs in about one in ten patients treated with PROCARDIA. This edema occurs primarily in the lower extremities and usually responds to diuretic therapy. With patients whose angina is complicated by congestive heart failure, care should be taken to differentiate this peripheral edema from the effects of increasing left ventricular dysfunction.

Drug Interactions: Beta-adrenergic blocking agents: (See Indications and Warnings.) Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of PROCARDIA and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.

Long-acting nitrates: PROCARDIA may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.

Digitalis: Administration of PROCARDIA with digoxin increased digoxin levels in nine of twelve normal volunteers. The average increase was 45%. Another investigator found no increase in digoxin levels in thirteen patients with coronary artery disease. In an uncontrolled study of over two hundred patients with congestive heart failure during which digoxin blood levels were not measured, digitalis toxicity was not observed. Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing PROCARDIA to avoid possible over- or under-digitalization.

Carcinogenesis, mutagenesis, impairment of fertility: When given to rats prior to mating, nifedipine caused reduced fertility at a dose approximately 30 times the maximum recommended human dose.

Pregnancy: Category C. Please see full prescribing information with reference to teratogenicity in rats, embryotoxicity in rats, mice and rabbits, and abnormalities in monkeys.

ADVERSE REACTIONS: The most common adverse events include dizziness or light-headedness, peripheral edema, nausea, weakness, headache and flushing each occurring in about 10% of patients, transient hypotension in about 5%, palpitation in about 2% and syncope in about 0.5%. Syncopal episodes did not recur with reduction in the dose of PROCARDIA or concomitant antianginal medication. Additionally, the following have been reported: muscle cramps, nervousness, dyspnea, nasal and chest congestion, diarrhea, constipation, inflammation, joint stiffness, shakiness, sleep disturbances, blurred vision, difficulties in balance, dermatitis, pruritus, urticaria, fever, sweating, chills, and sexual difficulties. Very rarely, introduction of PROCARDIA therapy was associated with an increase in anginal pain, possibly due to associated hypotension.

In addition, more serious adverse events were observed, not readily distinguishable from the natural history of the disease in these patients. It remains possible, however, that some or many of these events were drug related. Myocardial infarction occurred in about 4% of patients and congestive heart failure or pulmonary edema in about 2%. Ventricular arrhythmias or conduction disturbances each occurred in fewer than 0.5% of patients.

Laboratory Tests: Rare, mild to moderate, transient elevations of enzymes such as alkaline phosphatase, CPK, LDH, SGOT, and SGPT have been noted, and a single incident of significantly elevated transaminases and alkaline phosphatase was seen in a patient with a history of gall bladder disease after about eleven months of nifedipine therapy. The relationship to PROCARDIA therapy is uncertain. These laboratory abnormalities have rarely been associated with clinical symptoms. Cholestasis, possibly due to PROCARDIA therapy, has been reported twice in the extensive world literature.

HOW SUPPLIED: Each orange, soft gelatin PROCARDIA CAPSULE contains 10 mg of nifedipine. PROCARDIA CAPSULES are supplied in bottles of 100 (NDC 0069-2600-66), 300 (NDC 0069-2600-72), and unit dose (10x10) (NDC 0069-2600-41). The capsules should be protected from light and moisture and stored at controlled room temperature 59° to 77°F (15° to 25°C) in the manufacturer's original container.

More detailed professional information available on request.

© 1982, Pfizer Inc.

 **LABORATORIES DIVISION**
PFIZER INC

(Continued on Page 310)

If the Western Journal didn't exist, Someone would have to invent it.

The Western Journal of Medicine fills several important needs. It's an especially useful and practical journal for physicians in practice. Also, it provides unique coverage of social and economic trends affecting medicine (the current issue is a good example). And, not least important, it's a voice for medicine in the West. Medical achievements in the Western states are brought to the attention of the profession at large and communication is maintained among Western physicians.

Undoubtedly you can think of several people—a friend in another part of the country, a colleague in the West, a student—who should be receiving the *Western Journal* regularly. Why not subscribe for them? The cost is low. A year's subscription is just \$10 in the United States and Canada (\$18 in all other countries). If you wish, we'll send a card announcing your gift.

Please mail this coupon with enclosed payment to:

WJ2/83

THE WESTERN JOURNAL OF MEDICINE — Circulation Department

731 Market Street, San Francisco, California 94103

Subscriptions: U.S. and Canada \$10 All other countries \$18

Enclosed is \$_____ to cover _____ subscriptions.

Send subscription

TO: _____

TO: _____

Street _____

Street _____

City _____ State _____ Zip _____

City _____ State _____ Zip _____

Specialty _____

Specialty _____

Gift Card to read "From _____"

Gift Card to read "From _____"

Motrin® Tablets (Ibuprofen)

CONTRAINDICATIONS

Anaphylactoid reactions have occurred in individuals hypersensitive to *Motrin* Tablets or with the syndrome of nasal polyps, angioedema and bronchospastic reactivity to aspirin, iodides, or other nonsteroidal anti-inflammatory agents.

WARNINGS

Peptic ulceration and GI bleeding, sometimes severe, have been reported. Ulceration, perforation and bleeding may end fatally. An association has not been established. Use *Motrin* Tablets under close supervision in patients with a history of upper gastrointestinal tract disease, after consulting ADVERSE REACTIONS. In patients with active peptic ulcer and active rheumatoid arthritis, try nonulcerogenic drugs, such as gold. If *Motrin* Tablets are used, observe the patient closely for signs of ulcer perforation or GI bleeding.

Chronic studies in rats and monkeys have shown mild renal toxicity with papillary edema and necrosis. Renal papillary necrosis has rarely been shown in humans treated with *Motrin* Tablets.

PRECAUTIONS

Blurred and/or diminished vision, scotomata, and/or changes in color vision have been reported. If these develop, discontinue *Motrin* Tablets and the patient should have an ophthalmologic examination, including central visual fields and color vision testing. **Fluid retention and edema** have been associated with *Motrin* Tablets; use with caution in patients with a history of cardiac decompensation or hypertension. In patients with renal impairment, reduced dosage may be necessary. Prospective studies of *Motrin* Tablets safety in patients with chronic renal failure have not been done. *Motrin* Tablets can inhibit platelet aggregation and prolong bleeding time. Use with caution in persons with intrinsic coagulation defects and on anticoagulant therapy. Patients should report signs or symptoms of **gastrointestinal ulceration** or bleeding, skin rash, weight gain, or edema. Patients on prolonged **corticosteroid therapy** should have therapy tapered slowly when *Motrin* Tablets are added. The anti-pyretic, anti-inflammatory activity of *Motrin* Tablets may mask inflammation and fever.

As with other nonsteroidal anti-inflammatory drugs, borderline elevations of liver tests may occur in up to 15% of patients. These abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy. Meaningful elevations of SGPT or SGOT (AST) occurred in controlled clinical trials in less than 1% of patients. Severe hepatic reactions, including jaundice and cases of fatal hepatitis, have been reported with ibuprofen as with other nonsteroidal anti-inflammatory drugs. If liver disease develops or if systemic manifestations occur (e.g. eosinophilia, rash, etc.), *Motrin* should be discontinued.

Drug interactions. *Aspirin*: used concomitantly may decrease *Motrin* blood levels.

Coumarin: bleeding has been reported in patients taking *Motrin* and coumarin.

Pregnancy and nursing mothers: *Motrin* should not be taken during pregnancy or by nursing mothers.

ADVERSE REACTIONS

The most frequent type of adverse reaction occurring with *Motrin* is gastrointestinal of which one or more occurred in 4% to 16% of the patients.

Incidence Greater Than 1% (but less than 3%) — Probable Causal Relationship

Gastrointestinal: Nausea,* epigastric pain,* heartburn,* diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, fullness of GI tract (bloating and flatulence); **Central Nervous System:** Dizziness,* headache, nervousness; **Dermatologic:** Rash* (including maculopapular type), pruritus; **Special Senses:** Tinnitus; **Metabolic/Endocrine:** Decreased appetite; **Cardiovascular:** Edema, fluid retention (generally responds promptly to drug discontinuation; see PRECAUTIONS).

Incidence Less Than 1% — Probable Causal Relationship**

Gastrointestinal: Gastric or duodenal ulcer with bleeding and/or perforation, gastrointestinal hemorrhage, melena, gastritis, hepatitis, jaundice, abnormal liver function tests; **Central Nervous System:** Depression, insomnia, confusion, emotional lability, somnolence, aseptic meningitis with fever and coma; **Dermatologic:** Vesiculobullous eruptions, urticaria, erythema multiforme, Stevens-Johnson syndrome, alopecia; **Special Senses:** Hearing loss, amblyopia (blurred and/or diminished vision, scotomata and/or changes in color vision) (see PRECAUTIONS); **Hematologic:** Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia (sometimes Coombs positive), thrombocytopenia with or without purpura, eosinophilia, decreases in hemoglobin and hematocrit; **Cardiovascular:** Congestive heart failure in patients with marginal cardiac function, elevated blood pressure, palpitations; **Allergic:** Syndrome of abdominal pain, fever, chills, nausea and vomiting; anaphylaxis; bronchospasm (see CONTRAINDICATIONS); **Renal:** Acute renal failure in patients with pre-existing significantly impaired renal function, decreased creatinine clearance, polyuria, azotemia, cystitis, hematuria; **Miscellaneous:** Dry eyes and mouth, gingival ulcer, rhinitis.

Incidence Less Than 1% — Causal Relationship Unknown**

Gastrointestinal: Pancreatitis; **Central Nervous System:** Paresthesias, hallucinations, dream abnormalities, pseudotumor cerebri; **Dermatologic:** Toxic epidermal necrolysis, photoallergic skin reactions; **Special Senses:** Conjunctivitis, diplopia, optic neuritis; **Hematologic:** Bleeding episodes (e.g., epistaxis, menorrhagia); **Metabolic/Endocrine:** Gynecomastia, hypoglycemic reaction; **Cardiovascular:** Arrhythmias (sinus tachycardia, sinus bradycardia); **Allergic:** Serum sickness, lupus erythematosus syndrome, Henoch-Schönlein vasculitis; **Renal:** Renal papillary necrosis.

*Reactions occurring in 3% to 9% of patients treated with *Motrin*. (Those reactions occurring in less than 3% of the patients are unmarked.) **Reactions are classified under "Probable Causal Relationship (PCR)" if there has been one positive rechallenge or if three or more cases occur which might be causally related. Reactions are classified under "Causal Relationship Unknown" if seven or more events have been reported but the criteria for PCR have not been met.

OVERDOSAGE

In cases of acute overdosage, the stomach should be emptied. The drug is acidic and excreted in the urine so alkaline diuresis may be beneficial.

DOSE AND ADMINISTRATION

Rheumatoid and osteoarthritis: Suggested dosage is 300, 400, or 600 mg t.i.d. or q.i.d. Do not exceed 2400 mg per day.

Mild to moderate pain: 400 mg every 4 to 6 hours as necessary.

Caution: Federal law prohibits dispensing without prescription.

Upjohn

THE UPJOHN COMPANY
Kalamazoo, Michigan 49001 U.S.A.

MED B-7-S

(Continued from Page 304)

sity of Utah). Park City. Monday-Friday. Yarrow. 25 hrs. \$300. Contact: Donald F. Summers, MD (801) 581-8664.

March 18-19—**Advanced Trauma Life Support** (Sponsor: University of Utah). Salt Lake City. Thursday-Friday. Salt Lake Hilton Inn. 14.5 hrs. \$375. Contact: Kim Tanner, RN (801) 533-6608.

March 21-25—**3rd Annual Nutrition in Contemporary Medicine Conference** (Sponsor: University of Utah). Park City. Monday-Friday. 29 hrs. \$225. Contact: Jennifer Fossum (801) 581-3581.

March 24-25—**Ethical, Legal and Religious Concerns in Reproductive Medicine** (Sponsor: University of Utah). Salt Lake City. Thursday-Friday. University of Utah Campus. 15 hrs. \$70. Contact: Robert Fineman, MD (801) 581-8943.

March 25-27—**Medical Imaging Update for the General Medical Community** (Sponsor: University of Utah). Salt Lake City. Friday-Sunday. Tri-Arc Travel Lodge. 15 hrs. \$95; \$55, residents. Contact: Rebecca Peay (801) 581-8188.

April 1—**Connective Tissue Genes: Their Structure and Expression in Cells of the Arterial Wall/Interdepartmental Research Seminar** (Sponsor: University of Utah). Salt Lake City. Friday. School of Medicine. 1 hr. No fee. Contact: Rosalie Lammle (801) 581-8664.

April 5-8—**The 5th Annual RMCOEH Occupational and Environmental Health Conference: Reproduction: The New Frontier in Occupational and Environmental Health Research** (Sponsor: University of Utah/RMCOEH). Park City. Tuesday-Friday. Prospector Square. Credit and fee to be announced. Contact: Ms. K. Bloesch (801) 581-5710.

April 8-9—**Fourth Annual Dixie Spring Symposium/Topics in Gastroenterology for Primary Care Physicians** (Sponsor: Dixie Medical Center). Four Seasons Resort Inn, St. George. Friday-Saturday. 12 hrs. \$110. Contact: Linda Sappington (801) 673-6981.

June 1-3—**Computers in Critical Care and Pulmonary Medicine** (Sponsor: University of Utah). Salt Lake City. Wednesday-Friday. Hotel Utah. 12 hrs. \$250. Contact: Vicky Larsen (801) 581-6393.

June 20-33—**Alcoholism and Other Drug Dependencies** (Sponsor: University of Utah). Salt Lake City. Monday-Thursday. University of Utah Campus. 25 hrs. Fee to be announced. Contact: James Swenson, MD (801) 581-7985.

(Continued on Page 314)

SNOWBIRD CONFERENCES

sponsored by the

University of Utah School of Medicine

FEBRUARY 28 TO MARCH 4, 1983

Advances in Internal Medicine

\$275, 22.5 hours Category I CME Credit

MARCH 7-11, 1983

Medical and Surgical Advances in Gastroenterology

\$275, 22.5 hours Category I CME Credit

PARK CITY CONFERENCE

MARCH 21-25, 1983

Nutrition in Contemporary Medicine

\$225, 29 hours Category I CME Credit

INFORMATION/
REGISTRATION: JENNIFER FOSSUM
Division of Gastroenterology
University Medical Center
Salt Lake City, UT 84132
(801) 581-3581

Brief Summary of Prescribing Information.

Indications and Usage: Management of anxiety disorders or short-term relief of symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with stress of everyday life usually does not require treatment with an anxiolytic.

Effectiveness in long-term use, i.e., more than 4 months, has not been assessed by systematic clinical studies. Reassess periodically usefulness of the drug for the individual patient.

Contraindications: Known sensitivity to benzodiazepines or acute narrow-angle glaucoma.

Warnings: Not recommended in primary depressive disorders or psychoses. As with all CNS-acting drugs, warn patients not to operate machinery or motor vehicles, and of diminished tolerance for alcohol and other CNS depressants.

Physical and Psychological Dependence: Withdrawal symptoms like those noted with barbiturates and alcohol have occurred following abrupt discontinuance of benzodiazepines (including convulsions, tremor, abdominal and muscle cramps, vomiting and sweating). Addiction-prone individuals, e.g. drug addicts and alcoholics, should be under careful surveillance when on benzodiazepines because of their predisposition to habituation and dependence. Withdrawal symptoms have also been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months.

Precautions: In depression accompanying anxiety, consider possibility for suicide.

For elderly or debilitated patients, initial daily dosage should not exceed 2mg to avoid oversedation. Terminate dosage gradually since abrupt withdrawal of any antianxiety agent may result in symptoms like those being treated: anxiety, agitation, irritability, tension, insomnia and occasional convulsions. Observe usual precautions with impaired renal or hepatic function. Where gastrointestinal or cardiovascular disorders coexist with anxiety, note that lorazepam has not been shown of significant benefit in treating gastrointestinal or cardiovascular component. Esophageal dilation occurred in rats treated with lorazepam for more than 1 year at 6mg/kg/day. No effect dose was 1.25mg/kg/day (about 6 times maximum human therapeutic dose of 10mg/day). Effect was reversible only when treatment was withdrawn within 2 months of first observation. Clinical significance is unknown; but use of lorazepam for prolonged periods and in geriatrics requires caution and frequent monitoring for symptoms of upper G.I. disease. Safety and effectiveness in children under 12 years have not been established.

ESSENTIAL LABORATORY TESTS: Some patients have developed leukopenia; some have had elevations of LDH. As with other benzodiazepines, periodic blood counts and liver function tests are recommended during long-term therapy.

CLINICALLY SIGNIFICANT DRUG INTERACTIONS: Benzodiazepines produce CNS depressant effects when administered with such medications as barbiturates or alcohol.

CARCINOGENESIS AND MUTAGENESIS: No evidence of carcinogenic potential emerged in rats during an 18-month study. No studies regarding mutagenesis have been performed.

PREGNANCY: Reproductive studies were performed in mice, rats, and 2 strains of rabbits. Occasional anomalies (reduction of tarsals, tibia, metatarsals, malrotated limbs, gastroschisis, malformed skull and microphthalmia) were seen in drug-treated rabbits without relationship to dosage. Although all these anomalies were not present in the concurrent control group, they have been reported to occur randomly in historical controls. At 40mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits which was not seen at lower doses. Clinical significance of these findings is not known. However, increased risk of congenital malformations associated with use of minor tranquilizers (chloridiazepoxide, diazepam and meprobamate) during first trimester of pregnancy has been suggested in several studies. Because use of these drugs is rarely a matter of urgency, use of lorazepam during this period should almost always be avoided. Possibility that a woman of child-bearing potential may be pregnant at institution of therapy should be considered. Advise patients if they become pregnant to communicate with their physician about desirability of discontinuing the drug. In humans, blood levels from umbilical cord blood indicate placental transfer of lorazepam and its glucuronide.

NURSING MOTHERS: It is not known if oral lorazepam is excreted in human milk like other benzodiazepines. As a general rule, nursing should not be undertaken while on a drug since many drugs are excreted in milk.

Adverse Reactions, if they occur, are usually observed at beginning of therapy and generally disappear on continued medication or on decreasing dose. In a sample of about 3,500 anxious patients, most frequent adverse reaction is sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%) and unsteadiness (3.4%). Less frequent are disorientation, depression, nausea, change in appetite, headache, sleep disturbance, agitation, dermatological symptoms, eye function disturbance, various gastrointestinal symptoms and autonomic manifestations. Incidence of sedation and unsteadiness increased with age. Small decreases in blood pressure have been noted but are not clinically significant, probably being related to relief of anxiety.

Overdosage: In management of overdosage with any drug, bear in mind multiple agents may have been taken. Manifestations of overdosage include somnolence, confusion and coma. Induce vomiting and/or undertake gastric lavage followed by general supportive care, monitoring vital signs and close observation. Hypotension, though unlikely, usually may be controlled with Levaterenol Bitartrate Injection U.S.P. Usefulness of dialysis has not been determined.

Ativan®
for (lorazepam) 
Anxiety

Dosage: Individualize for maximum beneficial effects. Increase dose gradually when needed, giving higher evening dose before increasing daytime doses. Anxiety, usually 2-3mg/day given b.i.d. or t.i.d.; dosage may vary from 1 to 10mg/day in divided doses. For elderly or debilitated, initially 1-2mg/day; insomnia due to anxiety or transient situational stress, 2-4mg h.s.

How Supplied: 0.5, 1.0 and 2.0mg tablets.

Wyeth Laboratories
Philadelphia, PA 19101



(Continued from Page 310)

July 11-15—**Diagnostic Microbiology and Immunology** (Sponsor: University of Utah). Jackson Hole, Wyoming. Monday-Friday. 25 hrs. Fee to be announced. Contact: John Matsen, MD (801) 581-5968.

August 15-19—**Pediatric Immunology and Infectious Disease** (Sponsor: University of Utah). Monday-Friday. Sun Valley, Idaho. 25 hrs. Fee to be announced. Contact: John Matsen, MD (801) 581-5968.

Note: Dates, times, places and programs are subject to change on occasion. Please check with the sponsoring organization or the Academy for details.

WASHINGTON

This listing of continuing medical education programs in Washington state is compiled by the Washington State Medical Association. To list Category 1 programs here please send information at least two months in advance to Continuing Medical Education, Washington State Medical Association, 2033 Sixth Avenue, Suite 900, Seattle, WA 98121; or phone (206) 623-4801.

Brochures and Registration Forms are available from the contact person or organization listed at the end of each course or in the course sponsors and contact information box.

February 17-18—**Winter Symposium in Emergency Medicine.** Wenatchee. Thursday-Friday. Thunderbird Motor Inn. Contact: Heidi Hilby, Executive Secretary, Washington Chapter ACEP, 2033 Sixth Avenue, Room 900, Seattle, WA 98121. (206) 623-4801.

February 19-26—**(IDAHO) Infectious Diseases.** Sun Valley. Saturday-Saturday. Elkhorn Resort. Contact: U/W.

February 24-25—**Contemporary Clinical Neurology.** Seattle. Thursday-Friday. Virginia Mason Medical Center. Contact: VMMC.

February 26-March 5—**(HAWAII) Management of Pain.** Kauai. Saturday-Saturday. Kauai Surf. Contact: U/W.

March 4-5—**High-Risk Infants of the 1980s.** Seattle. Friday-Saturday. U/W Health Sciences Building. Contact: U/W.

March 5-12—**(HAWAII) Future Directions and Update on Family Practice.** Kona. Saturday-Saturday. Sheraton Royal Waikoloa. Contact: U/W.

March 12-19—**(HAWAII) Office Gynecology, Ophthalmology, Otolaryngology, Urinary and Breast Disease.** Kona. Saturday-Saturday. Sheraton Royal Waikoloa. Contact: U/W.

March 16-18—**MKSAP Medical Knowledge Self-Assessment Program.** Seattle. Wednesday-Friday Virginia Mason Medical Center. Contact: VMMC.

COURSE SPONSORS AND CONTACT INFORMATION

CME HARBORVIEW—Contact: Gayle Splater, Cytology Continuing Education, Dept. of Pathology, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104. (206) 223-5953.

CME PIERCE COUNTY—Contact: Mrs. Maxine Bailey, Executive Director, College of Medical Education, 705 South Ninth, No. 203, Tacoma, WA 98405. (206) 627-7137.

U/W (UNIVERSITY OF WASHINGTON) — Contact: U/W School of Medicine, Div. of CME, SC-50, Seattle, WA 98195. (206) 543-1050.

VMMC (VIRGINIA MASON MEDICAL CENTER)—Contact: Sandra McDonald, Division of Continuing Medical Education, Virginia Mason Medical Center, 1100 Ninth Avenue, P.O. Box 900, Seattle, WA 98101. (206) 223-6898.

March 18—**Endocrine Day.** Seattle. Friday. U/W CDMRC. Contact: U/W.

March 18-19—**Sex Offenders.** Seattle. Friday-Saturday. U/W South Campus Center. Contact: U/W.

March 18-19—**Recent Developments in Occupational Medicine.** Seattle. Friday-Saturday. U/W Health Sciences Building. Contact: U/W.

March 19-26—**(HAWAII) Internal Medicine.** Maui. Saturday-Saturday. Royal Lahaina. Contact: U/W.

March 25-26—**Advanced Cardiac Life Support.** Seattle. Friday-Saturday. U/W Health Sciences Building. Contact: U/W.

March 26-April 2—**(HAWAII) Vascular Disease.** Maui. Saturday-Saturday. Royal Lahaina. Contact: U/W.

April 1-2—**Compensation Law/Public Policy/Back Pain.** Seattle. Friday-Saturday. Sheraton Hotel. Contact: U/W.

April 2—**Anesthesia Care Team Meeting.** Seattle. Saturday. Westin Hotel. Contact: Marcia Wahlman, Executive Secretary, Washington State Society of Anesthesiologists, 2033 Sixth Ave., Suite 900, Seattle, WA 98121. (206) 623-4801.

April 7-9—**Controversies in Colon and Rectal Surgery.** Seattle. Thursday-Saturday. Swedish Hospital and Medical Center, 747 Summit Avenue, Seattle. Contact: John Wright, MD, Director of Medical Education.

April 11-22—**Rehabilitation Medicine Review.** Seattle. Monday-Friday. Sheraton. Contact: U/W.

April 14-16—**Twelfth Annual Refresher Course in Diagnostic Radiology and Imaging Update Symposium.** Spokane. Thursday-Saturday. Sacred Heart Medical Center. Contact: Marvin J. Gottschall, MD, Director of Radiology, Sacred Heart Medical Center, TAF-C9, Spokane, WA 99220.

April 16—**Mason Clinic Day.** Seattle. Saturday. Virginia Mason Medical Center. Contact: VMMC.

April 28-29—**Financial Planning for Physicians.** Seattle. Thursday-Friday. Sheraton Hotel. Contact: U/W.

May 5-6—**Health Issues for Exercising Women.** Seattle. Thursday-Friday. U/W Health Sciences Building. Contact: U/W.

May 6—**Primary Care Urology.** Seattle. Friday. Virginia Mason Medical Center. Contact: VMMC.

May 13-14—**Hypertension.** Seattle. Friday-Saturday. Virginia Mason Medical Center. Contact: VMMC.

May 19—**Panic and Anxiety Disorders.** Seattle. Thursday. U/W Health Sciences Building. Contact: U/W.

May 19-20—**Diabetes.** Seattle. Thursday-Friday. U/W Health Sciences Building. Contact: U/W.

May 20-21—**Neuroendocrinology.** Seattle. Friday-Saturday. U/W Health Sciences Building. Contact: U/W.

May 20-21—**Prescription and Nonprescription Drugs.** Seattle. Friday-Saturday. Virginia Mason Medical Center. Contact: VMMC.

June 3—**Endocrine Day.** Seattle. Friday. U/W CDMRC. Contact: U/W.

June 3-4—**Acute Medical Problems.** Seattle. Friday-Saturday. Virginia Mason Medical Center. Contact: VMMC.

June 9-11—**Common Office Procedures.** Seattle. Thursday-Saturday. U/W Health Sciences Building. Contact: U/W.

June 23-24—**Nosocomial Infections Herpes Hepatitis.** Seattle. Thursday-Friday. U/W Health Sciences Building. Contact: U/W.


Cheer up a low cholesterol diet with Saffola.

Saffola margarine is perfect for your patients following a low-cholesterol diet.

Not just because Saffola has no cholesterol. And is higher in beneficial polyunsaturates than corn oil margarine, even Fleischmann's or Mazola.

But because Saffola margarine tastes great. Which could mean the difference if your patient strays or stays on his diet.

Absolutely no cholesterol and higher in beneficial polyunsaturates.



WESTERN STATE MEDICAL ASSOCIATIONS' MEETINGS

Alaska State Medical Association—4107 Laurel St., Anchorage 99504. (907) 277-6891. Annual Meeting: May 28-31, 1983, Cordova.

Arizona Medical Association, Inc.—810 W. Bethany Home Rd., Phoenix 85013. (602) 246-8901. Annual Meeting: May 19-21, 1983, Doubletree Inn, Tucson.

California Medical Association—731 Market St., San Francisco 94103. (415) 777-2000. Annual Meeting: March 11-16, 1983, Bonaventure Hotel, Los Angeles.

Colorado Medical Society—6825 E. Tennessee, Bldg. 2, Suite 500, Denver 80224. (303) 321-8590. Annual Meeting: October 12-14, 1983, Tamorrone Resort, Durango.

Hawaii Medical Association—320 Ward Ave., Suite 200, Honolulu 96814. (808) 536-7702. Annual Meeting: 1983—date and place to be announced.

Idaho Medical Association—407 W. Bannock St., P.O. Box 2668, Boise 83701. (208) 344-7888. Annual Meeting: July 20-23, 1983, Sun Valley.

Montana Medical Association—2012 11th Ave., Suite 12, Helena 59601. (406) 433-4000. Annual Meeting: October 6-8, 1983, Edgewater Resort, Missoula.

Nevada State Medical Association—3660 Baker Lane, Reno 89502. (702) 825-6788. Annual Meeting: May 12-15, 1983, Elko Convention Center, Elko.

New Mexico Medical Society—303 San Mateo NE, Suite 204, Albuquerque 87108. (505) 266-7868. Annual Meeting: May 4-6, 1983, Four Seasons Motor Hotel, Albuquerque.

Oregon Medical Association—5210 S.W. Corbett Ave., Portland 97201. (503) 226-1555. Annual Scientific Session: November 3-4, 1983, Thunderbird, Jantzen Beach.

Utah State Medical Association—540 East Fifth South, Salt Lake City 84102. (801) 355-7477. Annual Meeting September 15-16, 1983, Park City.

Washington State Medical Association—900 United Airlines Bldg., 2033 6th Ave., Seattle 98121. (206) 623-4801. Annual Meeting: September 22-25, 1983, Westin Hotel, Seattle.

Wyoming Medical Society—P.O. Drawer 4009, Cheyenne 82003-4009. (307) 635-2424. Winter Seminar: January 21-22, 1983, Rawlins; Annual Meeting: June 29-July 2, 1983, Jackson Lake Lodge, Moran.

June 26-July 1—**(OREGON) Office Management of Common Psychiatry Problems.** Sunriver. Sunday-Friday. Sunriver Resort. Contact: U/W.

July 1-3—**(OREGON) Scientific Aspects of Dance.** Ashland. Friday-Sunday. Southern Oregon College. Contact: U/W.

July 6-9—**(OREGON) Ethical and Legal Aspects of Medical Practice.** Gleneden. Wednesday-Saturday. Salishan Resort. Contact: U/W.

July 10-15—**(OREGON) Medicine and Society in History.** Sunriver. Sunday-Friday. Sunriver Resort. Contact: U/W.

July 21-22—**American College of Physicians MKSAP VI.** Seattle. Thursday-Friday. U/W Health Sciences Building. Contact: U/W.

July 27-29—**The Burn Wound and the Burn Patient.** Seattle. Wednesday-Friday. Seattle Westin Hotel. Contact: U/W.

July 28-30—**Debates in Otolaryngology.** Seattle. Thursday-Saturday. Westin Hotel. Contact: U/W.

July 29-31—**Washington State Society of Anesthesiologists: Seafair V Anesthesia Meeting.** Seattle. Friday-Sunday. Sheraton. Contact: Washington State Society of Anesthesiology, Marcia Wahlman, Executive Secretary, 2033 Sixth Avenue, Suite 900, Seattle, WA 98121. (206) 623-4801.

August 4-5—**Sports Medicine Summer 1983.** Seattle. Thursday-Friday. U/W Health Sciences Building. Contact: U/W.

August 4-6—**Pharmacotherapy and Psychotherapy.** Seattle. Thursday-Saturday. U/W Health Sciences Building. Contact: U/W.

August 25-26—**Urology for Urologists.** Seattle. Thursday-Friday. U/W Health Sciences Building. Contact: U/W.

WYOMING

June 29-July 2—**Wyoming Medical Society Annual Meeting.** Moran. Wednesday-Saturday. Jackson Lake Lodge. For information contact: Wyoming Medical Society, PO Drawer 4009, Cheyenne, WY 82003-4009.

July 11-15—**Diagnostic Microbiology and Immunology** (Sponsor: University of Utah). Jackson Hole. Monday-Friday. 25 hrs. Fee to be announced. Contact: John Matsen, MD (801) 581-5968.

Index to The Western Journal of Medicine Advertising

AMA	
Health Reporting/Radio-TV Conference	312
AYERST LABORATORIES	
Inderide	178, 179, 180
BANKERS INVESTMENT COMPANY, THE	198
BONAVENTURE HOTEL, LOS ANGELES	203
BOOTS PHARMACEUTICAL CO.	
Ru-Tuss	302, 303
Zorpin	192, 193, 194
BOYLE & COMPANY/PHARMACEUTICALS	
Citra Forte Syrup/Citra Forte Capsules	172
BURROUGHS WELLCOME CO.	
Zyloprim	289
CLASSIFIED	294, 296, 298
COOPERATIVE OF AMERICAN PHYSICIANS	
Mutual Protection Trust	300
CPS MEDICAL BILLING SYSTEMS	295
DOCTORS' CO., THE	171
ELI LILLY & COMPANY	
Ceclor	297
GENERAL ARABIAN MEDICAL & ALLIED SERVICES LTD.	195
KEY PHARMACEUTICALS INC.	
Theo-Dur	200, 201, 202
NORCAL MUTUAL INSURANCE CORP.	190
NORTHRIDGE HOSPITAL IN COOPERATION WITH AMERICAN CANCER SOCIETY	
Oncology Update '83	290
PFIZER	
Diabinese	196, 197, 198
Procordia	304, 305
PHYSICIANS & SURGEONS INSURANCE EXCHANGE	311
PRACTICE SERVICES CORPORATION	182
RESEARCH INDUSTRIES INC.	
Rimso-50—Rimso-100	307
RCI COMPUTER SERVICES	291
ROCHE LABORATORIES	
Medical Education	183, 184
Dalmane	2nd cover, 167, 168
Limbitrol	3rd and 4th covers
SMITH KLINE & FRENCH LABORATORIES	
Dyazide	204
E. R. SQUIBB & SONS	
Capoten	174, 175
Corgard	185, 186, 187, 188
Velosef	317, 318, 319, 320
UNIVERSITY MICROFILMS INTERNATIONAL	168
UNIVERSITY OF SOUTHERN CALIFORNIA	
SCHOOL OF MEDICINE AND	
DEPARTMENT OF OBSTETRICS & GYNECOLOGY	298
UNIVERSITY OF UTAH SCHOOL OF MEDICINE	
Snowbird Conferences	310
UPJOHN CO., THE	
Motrin	308, 309, 310
US ARMY RECRUITING	299
USV LABORATORIES	
Hygroton-Regional	169
WESTERN JOURNAL OF MEDICINE, THE	
Subscription	306
WHITEHALL LABORATORIES	
Semicid	301
WISELY FOODS	
Saffola Margarine	315
WYETH LABORATORIES	
Ativan Oral	313, 314